| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Esperion Therapeutics, Inc.$3.18
+0.01 (+0.31%)
C 54Pipeline Score Undervalued Pharma · Commercial
Market Cap
805.76 M
EPS
-0.06
P/E Ratio
-
Value Trade
78.71 M
SEC Financials
Q1 2026Dilution Risk
Revenue
80.10 M
R&D Expenses
8.99 M
Operating CF
-27.72 M
Total Assets
462.53 M
Total Liabilities
770.46 M
Equity
-307.93 M
D/E Ratio
12,345
0.32 %
Week
62.18 %
1 Month
-10.57 %
3 Month
6.1 %
6 Month
-84.94 %
5 Year
-81.59 %
All Time
Cash Data
Cash Position
280.36 M
Monthly Burn
9.24 M
Runway
28.4 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
59.09 M
52 Week Range
0.79 - 4.18
% held by Insiders
6.08 %
% held by Institutions
72.07 %
Enterprise Value
1.19 B
Total Shares
239.09 M
Short %
7.43 %
Float Shares
234.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Esperion Therapeutics, Inc.
887Total events
15Upcoming
273Tier-1 (high impact)
2015 – 2036Coverage
Upcoming catalysts 15
2027
T2Timing Guidance
Esperion expects to complete clinical requirements and commercialize triple combinations in 2027
2027
T2Trial Initiation
Goal to complete clinical requirements and commercialize triple combinations in 2027
2027
T2Product Launch
Triple combination products (bempedoic acid, ezetimibe, atorvastatin or rosuvastatin) on track for commercialization in 2027
TBD
T2Hatch Waxman Litigation
Pending patent litigation against remaining ANDA filers (Alkem, Aurobindo, MSN, Renata, Sandoz)
TBD
T2Milestone Payment
Potential milestone payments up to $180 million tied to commercial and regulatory achievements
Event history 872
May 25, 2026
◆Oral Presentationbempedoic acidApprovedPresentation
Factors associated with enhanced LDL-C reductions from CLEAR Outcomes presented at EAS 2026
hypercholesterolemiasource ↗
May 24, 2026
◆Oral Presentationbempedoic acidApprovedPresentation
Bempedoic Acid In Children Aged 6-17 Years With Heterozygous Familial Hypercholesterolaemia: A Phase 2 Study presented at EAS Congress 2026
heterozygous familial hypercholesterolemiasource ↗
Apr 13, 2026
◆Oral PresentationPresentation
Esperion to participate in 25th Annual Needham Virtual Healthcare Conference
Q2 2026
◆Timing GuidanceNILEMDOApprovedPresentation
Expecting meaningful private payer coverage in Q2 2026
Q2 2026
▲Product LaunchNILEMDOApprovedPost-Market
Commercial launch of NILEMDO in Canada
reduction of LDL-Cholesterol in Canadians at risk of cardiovascular diseasesource ↗
Q2 2026
◆Other Regulator MilestoneEnbumystApprovedEx-US Regulatory
Transaction expected to close in Q2 2026
edema associated with congestive heart failure, hepatic and renal diseasesource ↗
Q2 2026
▲Quarterly UpdateCorporate
Expecting meaningful private payer coverage for NILEMDO in Q2 2026
Drug Pipeline Intelligence
C54
Pipeline Score $2.8B
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored3.5x
rNPV / MCap Top 82%
Micro Cap (rank 165 of 911)
Percentile RankEsperion Therapeutics, Inc. carries a moderate pipeline score (54/100), with $7.0B risk-adjusted pipeline value, led by ETC-1002 in Hypercholesterolemia (Phase 3), across $91B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ETC-1002 Small molecule | Hypercholesterolemia | Phase 3 | NCT01941836 | 53% | $3.2B | COMPLETED | 2,969 | - | - | Nov 1, 2014 | - | Mar 29, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
bempedoic acid | heterozygous familial hypercholesterolemia | Phase 2 | 2026-05-26 | 30% or greater reduction in LDL-C; 42% of patients in the bempedoic acid arm demonstrated a ≥30% LDL‐C reduction at 3 months; LDL-C reduction in pediatric patients (range 6-25%) Read More | Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 Read More | |
bempedoic acid | heterozygous familial hypercholesterolemia | Phase 2 | 2026-05-26 | 30% or greater reduction in LDL-C; 42% of patients in the bempedoic acid arm demonstrated a ≥30% LDL‐C reduction at 3 months; LDL-C reduction in pediatric patients (range 6-25%) Read More | Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 Read More | |
bempedoic acid | heterozygous familial hypercholesterolemia | Phase 2 | 2026-05-26 | 30% or greater reduction in LDL-C; 42% of patients in the bempedoic acid arm demonstrated a ≥30% LDL‐C reduction at 3 months; LDL-C reduction in pediatric patients (range 6-25%) Read More | Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ESPR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ESPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ESPREsperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
Esperion has presented new data on bempedoic acid, demonstrating its efficacy in lowering LDL cholesterol in children aged 6-17 years during the European Atherosclerosis Society Congress 2026. The Phase 2 study showed no new safety concerns, reinforcing the potential use of bempedoic acid as a lipid-lowering therapy for pediatric patients with familial hypercholesterolemia. Additionally, post hoc analysis from the CLEAR Outcomes study highlighted factors that enhance the drug's effectiveness among adults, showcasing its role as an alternative for statin-intolerant patients.
Read more →ESPREsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion announced the grant of 260,000 restricted stock units (RSUs) to 23 new employees under its 2017 Inducement Equity Incentive Plan. This plan is designed for individuals not previously associated with the company as an incentive for them to join Esperion. The RSUs will vest over a period, promoting employee retention. Esperion continues to focus on its mission to develop therapies for cardiometabolic and rare diseases, bolstered by a strong U.S. presence and international approvals.
Read more →ESPREsperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
Esperion announced two new analyses of bempedoic acid to be presented at the EAS Congress 2026. The pediatric Phase 2 study showed significant LDL-C reductions in children with heterozygous familial hypercholesterolemia. Additionally, new findings from the CLEAR Outcomes trial identify factors linked to enhanced LDL-C reductions in adults, supporting further development of the treatment.
Read more →ESPR▲ +55.5%on this news
Esperion to be Acquired by ARCHIMED
Esperion Therapeutics has entered into a definitive agreement to be acquired by ARCHIMED for up to $1.1 billion. Shareholders will receive $3.16 per share in cash and may participate in up to $100 million in contingent milestone payments. The deal, which includes a premium of 58% to the recent share price, is expected to close in Q3 2026, pending approvals.
Read more →ESPR▲ +55.5%on this newsshared move
Esperion to be Acquired by ARCHIMED Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equ
Esperion Therapeutics has entered into a definitive acquisition agreement with ARCHIMED, valuing the company at approximately $1.1 billion in total equity. Shareholders are set to receive $3.16 per share in cash at closing, representing a substantial premium. The transaction also includes potential additional payments of up to $100 million based on future sales milestones, aiming to support Esperion's growth in cardiometabolic therapies. Following the closing, expected in Q3 2026, Esperion will operate as a privately held entity.
Read more →ESPREsperion to Report First Quarter 2026 Financial Results on May 7
Esperion Therapeutics, Inc. has announced its intention to report first quarter 2026 financial results on May 7, 2026, prior to market opening. Following this release, a management-hosted webcast is scheduled for 8:00 a.m. ET to discuss the results along with business updates. The company is noted for its development of innovative therapies for cardiometabolic and rare diseases, boasting a solid commercial infrastructure and global market presence.
Read more →ESPREsperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics has officially closed the acquisition of Corstasis Therapeutics, integrating its innovative product Enbumyst into its cardiovascular franchise. Enbumyst, the first FDA-approved nasal spray loop diuretic, is designed for the treatment of edema associated with congestive heart failure, and aligns with Esperion's strategic goals to address cardiometabolic diseases. The acquisition is expected to enhance Esperion's existing capabilities and commercial strategy, positioning the company for sustained revenue growth. However, there are uncertainties related to market acceptance and the operational integration of the new product.
Read more →ESPREsperion to Participate in 25th Annual Needham Virtual Healthcare Conference
Esperion Therapeutics (NASDAQ: ESPR) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The event will include a live webcast accessible through the company's investor and media section. Esperion is focused on developing therapies for cardiometabolic and rare diseases, and it markets non-statin treatments for low-density lipoprotein cholesterol. The company has a robust infrastructure that supports its operations in the U.S. and over 40 countries worldwide.
Read more →ESPREsperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
Esperion presented new data at the ACC.26 showing that bempedoic acid significantly reduces the risk of ischemic stroke by 22% compared to placebo. The analysis also indicated that patients with autoimmune or inflammatory diseases benefit similarly from bempedoic acid as those without. These findings reinforce the drug's value in managing cardiovascular risk, especially for statin-intolerant patients.
Read more →ESPREsperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
Esperion announced that two abstracts from the CLEAR Outcomes trial will be presented at the American College of Cardiology's 2026 Annual Scientific Session. The analyses aim to enhance understanding of cardiovascular risk reduction in diverse patient populations. CEO Sheldon Koenig emphasized the importance of these insights for patients often overlooked in traditional studies.
Read more →ESPR▲ +10.2%on this newsshared move
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Esperion's bempedoic acid has been included in the 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia with multiple Class 1 recommendations. This inclusion endorses its use for LDL-C lowering and cardiovascular risk reduction, especially for patients with statin intolerance. The guideline emphasizes aggressive combination therapy and reintroduces LDL-C targets, affirming the importance of earlier treatment. The recommendations suggest bempedoic acid can be used effectively alongside other therapies such as ezetimibe and PCSK9 mAbs.
Read more →ESPR▼ -11.2%on this news
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Esperion has reported robust financial results for the fourth quarter and full year 2025, with total revenue increasing by 21% year-over-year. Notably, the company's U.S. net product revenue grew by 38%, highlighting strong market performance. A key aspect of Esperion's strategy involves the planned acquisition of Corstasis Therapeutics, which is expected to enhance its cardiovascular franchise. The company remains focused on expanding its portfolio and advancing its Vision 2040 strategy for long-term growth.
Read more →ESPRHLS Therapeutics Announces NILEMDO™ (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease
HLS Therapeutics has launched NILEMDO (bempedoic acid) in Canada, approved by Health Canada to reduce LDL-C levels and cardiovascular risk in patients unable to achieve target levels. The drug is now available by prescription and is expected to benefit over half a million Canadians. Supported by the CLEAR Outcomes trial, NILEMDO provides a new option for patients intolerant to statins.
Read more →ESPR/C O R R E C T I O N -- HLS Therapeutics Inc./
HLS Therapeutics has launched NILEMDO (bempedoic acid) in Canada, aimed at reducing LDL-C levels in patients at risk of cardiovascular disease. Approved by Health Canada in November 2025, NILEMDO offers an alternative for patients who cannot achieve LDL-C targets with existing therapies. The launch is backed by robust clinical trial data demonstrating its effectiveness in lowering cardiovascular risks.
Read more →ESPR▼ -11%on this newsshared move
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics has entered a definitive agreement to acquire Corstasis Therapeutics, enhancing its cardiovascular franchise with the innovative Enbumyst (bumetanide nasal spray). This product is the first FDA-approved nasal spray diuretic for treating edema related to congestive heart failure and other conditions. The acquisition is expected to close in Q2 2026, with a potential market opportunity exceeding $4 billion.
Read more →ESPREsperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
Esperion announced it will report its fourth quarter and full year 2025 financial results on March 10, 2026. The company will host a webcast to discuss these results and provide business updates. Esperion focuses on developing innovative therapies for cardiometabolic and rare diseases and has a strong market presence in the U.S. and globally.
Read more →ESPREsperion to Participate in The 2026 Citizens Life Sciences Conference
Esperion Therapeutics (NASDAQ: ESPR) announced its participation in the upcoming 2026 Citizens Life Sciences Conference scheduled for March 11, 2026. The conference will include a webcast accessible through the company's website, with a replay available after the live event. Esperion is recognized for its innovative cardiometabolic therapies and has a solid international presence, holding approvals in more than 40 countries.
Read more →ESPREsperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040
Esperion has entered a settlement with Alkem Laboratories to prevent the marketing of generic versions of its drugs NEXLETOL and NEXLIZET until April 19, 2040. This agreement resolves litigation related to Alkem's ANDA filings. However, the company continues to face ongoing patent litigation with other parties, which may affect the exclusivity of its products in the future. Despite these challenges, Esperion maintains a strong market presence and is advancing its pipeline in cardiometabolic therapies.
Read more →ESPR▼ -8.5%on this news· ran to -19% by day 3
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Esperion provided a comprehensive business update during the 44th Annual J.P. Morgan Healthcare Conference, highlighting an expected significant increase in net product sales and total revenue for the full year 2025. The company introduced its Vision 2040 growth strategy, focusing on expanding its product pipeline into rare diseases and enhancing its cardiovascular offerings. Esperion has also achieved considerable growth in its commercial strategies, including growing prescription equivalents and expanding reimbursement access. However, anticipated operating expenses for 2026 are projected to be considerable.
Read more →ESPREsperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
Esperion will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will include a fireside chat and will be accessible via a live webcast. The company focuses on innovative therapies for cardiometabolic and rare diseases, currently marketing two non-statin oral therapies.
Read more →ESPREsperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
Esperion's bempedoic acid has been included as a first-line therapy for LDL-C lowering in patients with peripheral artery disease and diabetes, according to the 2025 ACC Scientific Statement. This endorsement highlights its role in reducing cardiovascular and limb risks. The company anticipates further recognition in upcoming treatment guidelines.
Read more →ESPREsperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Esperion's partner, Otsuka Pharmaceutical, has launched NEXLETOL in Japan for treating hypercholesterolemia after receiving national pricing approval. This launch represents a significant commercial achievement for Esperion, as they will receive a $90 million payment and potential future royalties based on sales. The launch aims to enhance cardiovascular health for patients managing LDL-C levels in Japan.
Read more →ESPREsperion to Participate in Piper Sandler 37th Annual Healthcare Conference
Esperion Therapeutics, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025. This participation highlights the company's ongoing efforts to engage with stakeholders in the biopharmaceutical community. Esperion is recognized for its FDA-approved oral medications for patients at risk of cardiovascular disease, and is advancing its research on ATP citrate lyase inhibitors. The webcast of the presentation will be accessible on the company's website, showcasing its commitment to transparency and investor relations.
Read more →ESPREsperion Partner HLS Therapeutics Announces Approval of NILEMDO for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Esperion announced that HLS Therapeutics has received approval from Health Canada for NILEMDO, aimed at reducing LDL-Cholesterol in Canadians at risk of cardiovascular disease. This approval is part of Esperion's strategy to expand access to its bempedoic acid products. The commercial launch is anticipated for Q2 2026, highlighting the urgency to address heart disease, which significantly impacts Canadian adults. Esperion's continued commitment to innovative therapies reflects its dedication to improving patient outcomes on a global scale.
Read more →ESPR▲ +8.3%on this news
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
Esperion presented new data from the CLEAR Outcomes study at the AHA Scientific Sessions 2025, highlighting the efficacy of bempedoic acid in reducing major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in patients not on other lipid-lowering therapies. The findings support bempedoic acid as a foundational therapy for those intolerant to statins.
Read more →ESPR▼ -15%on this newsshared move
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
Esperion reported a strong financial performance for Q3 2025, with total revenue increasing by 69% year-over-year to $87.3 million. The company reached a settlement with Dr. Reddy's Laboratories, preventing the marketing of generic versions of its products until 2040. Additionally, bempedoic acid received a Level 1a recommendation in updated guidelines, and Otsuka secured regulatory approval for NEXLETOL in Japan, which will provide milestone payments. Despite these positives, the company reported increased net losses and a decline in cash reserves.
Read more →ESPREsperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
Esperion has appointed John Harlow as Chief Commercial Officer, effective November 17, 2025. Harlow brings over two decades of experience in pharmaceutical leadership and is expected to enhance Esperion's commercial strategies. His previous success at Melinta Therapeutics, where he significantly increased revenue, positions him well to drive growth for Esperion's cardiovascular therapies.
Read more →ESPRstructure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global bioph
Esperion has appointed John Harlow as its new Chief Commercial Officer, effective November 17, 2025. Harlow, who has over twenty years of experience in the pharmaceutical industry, is expected to enhance Esperion's commercial strategies and drive the growth of its cardiovascular therapies. Under his leadership, Esperion aims to expand market adoption and improve access to its approved medications, namely NEXLETOL and NEXLIZET, while continuing to develop innovative treatments through its ACLYi program.
Read more →ESPREsperion to Participate in Jefferies Global Healthcare Conference - London
Esperion Therapeutics will present at the Jefferies Global Healthcare Conference in London on November 18, 2025. The company focuses on developing innovative treatments for cardiovascular disease, including FDA-approved oral medications. Esperion is also advancing its pipeline with new drug designs aimed at improving patient outcomes.
Read more →ESPREsperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
Esperion will host a virtual key opinion leader event on November 11, 2025, to address the challenges of statin intolerance and its impact on patient outcomes. Led by VP LeAnne Bloedon, the event aims to foster dialogue among leading cardiovascular experts. CEO Sheldon Koenig emphasizes the urgency of finding innovative solutions for patients who struggle with statin therapy.
Read more →ESPR▲ +7%on this newsshared move
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
Esperion has announced that it will present new analyses from the CLEAR Outcomes trial at the AHA Scientific Sessions 2025. The presentations include an oral session on bempedoic acid monotherapy and a poster session on its effects on venous thromboembolism. These findings aim to address statin intolerance and enhance treatment options for patients with elevated LDL cholesterol.
Read more →ESPREsperion to Report Third Quarter 2025 Financial Results on November 6
Esperion has announced plans to report its financial results for the third quarter of 2025 on November 6, prior to market opening. Following the release, company management will conduct a webcast at 8:00 a.m. ET to discuss the findings and provide business updates. Esperion focuses on addressing unmet needs in cardiovascular treatment and is working on new drug development in this area, highlighting its commitment to innovation and patient care.
Read more →ESPR▲ +5.2%on this news
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
Esperion has nominated ESP-2001, a highly-specific allosteric ACLY inhibitor, as a preclinical development candidate for primary sclerosing cholangitis (PSC). The company plans to initiate IND-enabling studies with the goal of filing an IND with the FDA for first-in-human clinical studies in 2026. PSC currently has no approved treatments, highlighting the potential significance of ESP-2001 in addressing this unmet medical need.
Read more →ESPR▼ -16.8%on this news
Esperion Announces Pricing of Public Offering of Common Stock
Esperion Therapeutics has announced the pricing of a public offering for 30 million shares of common stock at $2.50 each, aiming to raise approximately $75 million. The offering is set to close on or about October 9, 2025, pending customary conditions. This move supports Esperion's focus on developing non-statin medications for managing elevated LDL cholesterol.
Read more →ESPREsperion Announces Proposed Public Offering of Common Stock
Esperion Therapeutics has announced a proposed public offering of its common stock to raise capital. The offering will be underwritten by Piper Sandler & Co. and Cantor Fitzgerald & Co., with an option for underwriters to purchase additional shares. The company intends to use the proceeds to support the development and commercialization of its non-statin medicines for managing LDL cholesterol, though completion of the offering is contingent on market conditions.
Read more →ESPREsperion Corporate Presentation © 2025 Esperion Therapeutics, Inc. All rights reserved. October 2025 2 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This pre s
Esperion Therapeutics presented important safety information regarding NEXLIZET and NEXLETOL, highlighting various adverse reactions observed during clinical trials. Key risks include tendon rupture, serious hypersensitivity reactions, and complications related to elevated uric acid levels. The presentation emphasized the need to discontinue treatment upon recognizing certain adverse events and to monitor patients closely, especially those with a history of tendon disorders. The information aims to inform both healthcare providers and patients about the benefits and risks associated with these therapies.
Read more →ESPR▲ +13.8%on this newsshared move
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 19, 2040
Esperion has entered a settlement agreement with Dr. Reddy's Laboratories, which will prevent the marketing of generic versions of NEXLETOL and NEXLIZET in the U.S. prior to April 19, 2040. This legal resolution also ensures that there are no remaining challenges regarding the validity of U.S. Patent No. 7,335,799, which protects bempedoic acid. Earlier this year, Esperion reached similar agreements with other companies regarding their generic applications for NEXLETOL. The ongoing patent litigation with additional defendants remains unresolved, potentially affecting future market entry of generics.
Read more →ESPREsperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL in Japan for the Treatment of Hypercholesterolemia
Esperion has announced that its partner, Otsuka Pharmaceutical, received regulatory approval to market NEXLETOL in Japan for treating hypercholesterolemia. This approval marks a significant step in Esperion's international growth strategy, complementing its existing markets in the U.S. and Europe. The collaboration agreement allows Esperion to receive milestone payments upon regulatory approval and sales achievements in Japan, further supporting its business expansion efforts. NEXLETOL is a non-statin therapy aimed at patients seeking alternatives for lowering LDL-C levels.
Read more →ESPREsperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Esperion Therapeutics has announced that its drug bempedoic acid has received a Level 1a recommendation for LDL-C lowering in the updated ESC/EAS guidelines for managing dyslipidaemias. This marks a significant endorsement recognizing bempedoic acid as the only non-statin therapy recommended for cardiovascular risk reduction. The updated guidelines emphasize an aggressive approach towards early combination therapy for patients unable to use statins. Esperion also plans to capitalize on this recognition as it continues to advance its portfolio of lipid-lowering treatments in the U.S. market.
Read more →ESPREsperion to Participate in Upcoming September Investor Conferences
Esperion announced its participation in two prominent investor conferences in September 2025, aiming to enhance investor engagement. The events include the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference, both located in New York. Esperion continues to develop innovative therapies for cardiovascular disease, showcasing its commitment to addressing patient needs through an advanced pipeline and recent commercial successes.
Read more →ESPR▲ +8.7%on this news· ran to +29% by day 1shared move
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
Esperion reported its second-quarter financial results for 2025, showing a 12% increase in total revenue to $82.4 million. The company achieved a 42% growth in U.S. net product revenue, marking a significant positive trend. Esperion also highlighted its first quarter of operating income, with expectations for sustainable profitability beginning in early 2026. However, net losses were noted for the quarter and year-to-date, alongside a marked decrease in collaboration revenue.
Read more →ESPR▲ +6.1%on this news· ran to +31% by day 3
Esperion to Report Second Quarter 2025 Financial Results on August 5
Esperion announced that it will report its second quarter financial results for 2025 on August 5. A webcast will be held to discuss these results and provide further business updates. The company focuses on developing non-statin medications for patients at risk of cardiovascular disease. Esperion has also been advancing its pipeline with new drug candidates, particularly ATP citrate lyase inhibitors.
Read more →ESPR▲ +5.4%on this news
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040
Esperion has announced a settlement agreement with Accord Healthcare, resolving patent litigation over the generic version of NEXLETOL. The settlement prohibits Accord from marketing a generic version prior to April 19, 2040, except under certain conditions. However, litigation against other defendants remains ongoing, which could impact the timeline for potential generics in the future. Esperion continues to focus on its pipeline and efforts to address cardiovascular diseases with its innovative treatments.
Read more →ESPREsperion Appoints Craig Thompson to Board of Directors
Esperion has appointed Craig Thompson, CEO of Cerevance, to its Board of Directors, expanding the board to eight members. Thompson's extensive experience in biopharmaceutical leadership is seen as a significant asset as Esperion continues its mission in cardiovascular and cardiometabolic drug development. With a strong background in pharmaceutical commercialization, Thompson expresses enthusiasm for collaborating with the team to drive innovative solutions to combat cardiovascular diseases. Esperion aims to leverage Thompson's expertise to enhance their growth and innovation in the industry.
Read more →ESPR▲ +8.1%on this news· ran to +37% by day 3
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040
Esperion has entered into a settlement agreement with Hetero USA, preventing it from marketing a generic version of NEXLETOL until April 19, 2040. This agreement is part of the resolution to patent litigation relating to Hetero's Abbreviated New Drug Application. However, the company faces ongoing patent litigation against other defendants, creating uncertainty regarding generic competition for NEXLETOL in the future. Esperion continues to position itself as a pivotal player in the cardiovascular therapy space.
Read more →ESPR▲ +5.2%on this news
Esperion to Participate in Upcoming June Investor Conferences
Esperion (NASDAQ: ESPR) has announced its participation in two upcoming investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference in New York and the Goldman Sachs Global Healthcare Conference in Miami. These events will be webcasted and available for replay on their investor relations website. Esperion is focused on developing new biopharmaceuticals for cardiovascular disease, including its unique FDA-approved therapies and attention to advancing its pipeline.
Read more →ESPREsperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040
Esperion has reached a settlement with Micro Labs that prevents the marketing of a generic version of its drug NEXLETOL until April 19, 2040. This agreement resolves existing patent litigation and confirms Esperion's proprietary rights for a significant period. However, ongoing litigation with other defendants concerning similar matters continues, which may pose future risks to Esperion's market exclusivity. The company's broader strategy remains focused on addressing unmet cardiovascular needs through innovative therapies.
Read more →ESPR▼ -10.6%on this newsshared move
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
Esperion (NASDAQ: ESPR) will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025. The live webcast of the conference will be available on the company's website, with a replay accessible for 90 days post-event. Esperion continues to develop innovative treatments for cardiovascular disease, including its FDA-approved oral non-statin medicines and next-generation ACLY inhibitors.
Read more →ESPREsperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada
Esperion Therapeutics has entered into a license and distribution agreement with HLS Therapeutics to exclusively commercialize its products NEXLETOL and NEXLIZET in Canada. As part of the agreement, Esperion will receive an upfront payment, milestone payments, and royalties based on product sales. This partnership highlights the potential to address the needs of approximately 2.6 million Canadians diagnosed with heart disease while expanding the reach of Esperion's therapies in international markets.
Read more →ESPR▼ -7.1%on this news· ran to -24% by day 3shared move
Esperion Reports First Quarter 2025 Financial Results
Esperion reported its Q1 2025 financial results, highlighting a total revenue of $65.0 million, a 53% decrease from the previous year. Excluding a one-time milestone from Q1 2024, total revenue would have grown by 63%. The U.S. net product revenue saw a significant increase of 41%, alongside bempedoic acid earning Level 1a recommendations in new clinical guidelines. The company also expanded its portfolio by introducing a novel program targeting Primary Sclerosing Cholangitis, which has substantial market potential.
Read more →ESPREsperion to Participate in The Citizens Life Sciences Conference
Esperion (NASDAQ: ESPR) will participate in the webcasted Citizens Life Sciences Conference on May 8, 2025. This event underscores Esperion's commitment to addressing unmet medical needs, particularly in the cardiovascular sector, through its FDA-approved therapies. The company continues to innovate with its next-generation ATP citrate lyase inhibitors and aims to enhance its market position through strategic partnerships and development of its pre-clinical pipeline.
Read more →ESPR▼ -7.2%on this newsshared move
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
Esperion has unveiled promising new research supporting its development candidates targeting primary sclerosing cholangitis (PSC) at their R&D Day event. The company is focusing on novel allosteric ACLY inhibitors that have shown effectiveness in reducing liver injury and inflammation across various preclinical models. With no approved therapies available for PSC, Esperion aims to address this significant unmet medical need. The lead candidate, ESP-1336, represents a natural extension of the company's metabolic portfolio, showcasing their internal R&D capabilities.
Read more →ESPREsperion to Report First Quarter 2025 Financial Results on May 6
Esperion Therapeutics has announced it will report its first quarter 2025 financial results on May 6, 2025, before the market opens. Following the announcement, the company will host a webcast to discuss the results and provide updates on its business. Esperion is recognized for its focus on developing FDA-approved oral medications for cardiovascular disease, and continues to advance its pre-clinical pipeline while leveraging international collaborations.
Read more →ESPR▼ -8.6%on this news
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
Esperion will host an R&D Day on April 24, 2025, in New York City, showcasing its advancements in cardiometabolic therapies, particularly focusing on ACLY inhibitors. The event will feature presentations by company leadership and leading experts in the field. Esperion aims to share insights into its research strategy, including the unveiling of a new indication and the lead candidate for further development. The company is progressing towards an Investigational New Drug Application based on promising pre-clinical results.
Read more →ESPRAbout Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The C
Esperion Therapeutics has appointed Robert E. Hoffman as an independent director, effective immediately, who will also take on the role of Chairperson of the Audit Committee starting May 29, 2025. He brings extensive financial and leadership experience in the biopharmaceutical sector. The company also announced that current board members Nicole Vitullo and Antonio M. Gotto, Jr. will resign as of June 1, 2025. This leadership transition aims to support Esperion’s ongoing commercialization efforts and development of innovative cardiovascular treatments.
Read more →ESPREsperion Appoints Robert E. Hoffman to Board of Directors
Esperion has appointed Robert E. Hoffman as an independent director, effective immediately. Hoffman will also serve as Chairperson of the Audit Committee starting May 29, 2025. His extensive experience in the biopharmaceutical industry is expected to benefit the company's commercialization efforts and expansion of its ACLY inhibitors pipeline. Concurrently, board members Nicole Vitullo and Antonio M. Gotto, Jr. will step down effective June 1, 2025.
Read more →ESPREsperion to Participate in 24th Annual Needham Virtual Healthcare Conference
Esperion Therapeutics, Inc. will attend the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:45 a.m. ET. The conference will be webcasted, and a replay will be available afterward for approximately 90 days. Esperion focuses on developing oral non-statin medications for cardiovascular disease to address patient needs. The company is also advancing its pre-clinical pipeline with innovative drug design based on CLSYi insights.
Read more →ESPREsperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
Esperion announced its alignment with the U.S. FDA to initiate Phase 3 clinical trials for bempedoic acid in pediatric patients with heterozygous and homozygous familial hypercholesterolemia. The decision follows confirmation of sufficient data to complete their Phase 2 study enrollment. The Phase 3 trials will assess the efficacy of bempedoic acid alone and in combination with ezetimibe, aiming to secure additional patent extension until June 2031. The studies are set to commence this year, marking a significant advancement in the treatment for these pediatric patients.
Read more →ESPR▲ +12%on this news
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
Esperion reported impressive financial results for Q4 2024, with total revenue rising by 114% year-over-year, bolstered by a 52% increase in U.S. net product revenue. The company is setting ambitious goals, focusing on revenue growth, operating profitability, and pipeline expansion. They've initiated the development of new triple combination products and are enhancing international market penetration. Esperion's robust financial standing empowers them to explore valuable cardiometabolic assets, promising a bright future in cardiovascular care.
Read more →ESPR▼ -7.1%on this newsshared move
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Australia
Esperion Therapeutics has partnered with CSL Seqirus for the exclusive commercialization of NEXLETOL and NEXLIZET in Australia and New Zealand. This deal allows Esperion to enhance its market presence and provide new treatment options for patients with cardiovascular disease. CSL Seqirus will handle marketing, regulatory approval, and reimbursement processes, while Esperion will receive upfront and milestone payments. The partnership aims to address the significant burden of cardiovascular diseases in both countries.
Read more →ESPREsperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
Esperion announced it will report its fourth-quarter and full-year 2024 financial results on March 4, 2025. Management will host a webcast at 8:00 a.m. ET to discuss the financial results and provide business updates. The company's ongoing focus is on developing oral, non-statin medicines approved by the FDA for patients with elevated LDL-C levels. Esperion is also advancing its pipeline with a focus on developing ATP citrate lyase inhibitors.
Read more →ESPR▲ +7.8%on this news
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
Esperion announced it will host a virtual key opinion leader event on January 22, 2025, focusing on LDL cholesterol management to prevent cardiovascular disease. The event will feature expert discussions around their FDA-approved medications, NEXLETOL and NEXLIZET. Patrick Moriarty, M.D., a leading physician in the field, will participate in the discussion. Esperion continues to advance its initiatives in the biopharmaceutical sector while addressing significant healthcare challenges.
Read more →ESPREsperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics (NASDAQ: ESPR) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The event will be webcasted, allowing for live access and a replay approximately two hours post-event. Esperion focuses on commercializing FDA-approved non-statin medicines for patients at risk of cardiovascular disease, with a strong emphasis on innovative drug development including ATP citrate lyase inhibitors (ACLYi). The company aims to solidify its position as a leading biopharmaceutical entity through partnerships and a robust pipeline.
Read more →ESPR▼ -12.2%on this news
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
Esperion has successfully completed significant refinancing transactions, including a $150 million secured term loan and a new $100 million convertible note, aimed at repaying a substantial portion of its existing convertible debt. The new arrangements will enable the company to strengthen its balance sheet, providing increased operational and financial flexibility. The investment is led by Athyrium Capital Management, alongside HealthCare Royalty, and will help Esperion focus on growing revenue from its bempedoic acid products, NEXLETOL and NEXLIZET. The refinancing will delay repayment of existing obligations, extending maturity for five years or more.
Read more →ESPR▼ -11.8%on this newsshared move
Esperion Announces $210 Million Convertible Debt Financing
Esperion has announced a $210 million convertible debt financing that involves issuing new Convertible Senior Subordinated Notes due 2030. The financing comprises exchange transactions for existing notes and cash contributions in a bid to enhance their financial capacity. Although this will lower future interest payments, it does not provide immediate cash proceeds for the company. The conversion options and restrictions inherent in the new notes may impact shareholder equity.
Read more →ESPR▼ -11.8%on this newsshared move
ESPERION ANNOUNCES $210
Esperion announced a $210 million transaction involving its convertible notes, which includes issuing $100 million worth of new convertible senior subordinated notes. The agreement will see the conversion of certain outstanding notes due in 2025 into new notes due in 2030. The net proceeds from this transaction are earmarked for general corporate purposes. However, the company will not gain cash from the exchange component of the deal, and the new notes come with specific restrictive covenants.
Read more →ESPR▼ -5.2%on this news· ran to -16% by day 1shared move
Esperion Partners with Neopharm to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics has entered a licensing agreement with Neopharm Israel for the exclusive commercialization of NEXLETOL (bempedoic acid) and NEXLIZET in Israel. The deal includes an upfront payment, milestone payments, and tiered royalties based on sales. Neopharm, with its extensive experience in successfully commercializing pharmaceutical products, will manage the commercialization efforts in Israel, Gaza, and the West Bank. This partnership is aimed at providing effective cardiovascular treatments to patients at risk of heart disease.
Read more →ESPR▲ +10.7%on this news
Esperion Announces New Drug Submissions in Canada for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
Esperion has filed New Drug Submissions with Health Canada for its oral medications NEXLETOL and NEXLIZET, which aim to lower LDL cholesterol and reduce cardiovascular risk. The company emphasizes the urgency of providing these treatments as heart disease is a leading cause of mortality in Canada. Although the products offer significant benefits, there are important safety warnings including risks of hypersensitivity reactions and tendon injuries associated with their use. Esperion's efforts highlight a commitment to addressing a critical health issue for millions of patients.
Read more →ESPREsperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
Esperion has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference scheduled for December 5, 2024. The event will be webcasted, allowing investors and the public to access the presentation live. A replay of the webcast will also be available on the company's website for approximately 90 days following the event.
Read more →ESPREsperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Esperion presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, revealing that bempedoic acid significantly reduces major adverse limb events in patients with Peripheral Artery Disease (PAD) who cannot take statins. The analysis showed a 36% reduction in these events compared to placebo. Additionally, the trial results indicated that bempedoic acid might help achieve lower LDL-C levels and warrants further exploration in managing cardiovascular risks. Presentations at such prominent meetings may enhance the recognition and clinical uptake of their therapies.
Read more →ESPREsperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
Esperion reported a strong financial performance for Q3 2024, with total revenue up 52% year-over-year, driven by significant growth in U.S. net product revenue. The company has successfully expanded its product labels and increased new prescriptions across commercial and Medicare payers. Despite a net loss of $29.5 million, Esperion's partnerships, particularly in Europe and Japan, highlight its growth potential in both markets. The company continues to deliver promising outcomes in its commercial and research initiatives.
Read more →ESPREsperion to Participate in Upcoming Jefferies London Healthcare Conference
Esperion (NASDAQ: ESPR) announced its participation in the 2024 Jefferies London Healthcare Conference, scheduled for November 19, 2024. The event will be available via a live webcast accessible on the company's investor and media section. A replay of the webcast will be available shortly after the event, archived for approximately 90 days for broader accessibility.
Read more →ESPREsperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
Esperion announced participation in the upcoming American Heart Association (AHA) Scientific Sessions 2024, featuring a prominent Late Breaker/Featured Science presentation and three poster presentations. The presentations will cover new insights from the CLEAR Outcomes Trial, focusing on bempedoic acid and its effects on patients with peripheral artery disease and statin intolerance. The event is scheduled for November 16-18, 2024, in Chicago, IL, and aims to address critical aspects of cardiovascular health management.
Read more →ESPREsperion to Report Third Quarter 2024 Financial Results on November 7
Esperion (NASDAQ: ESPR) has announced that it will release its third quarter 2024 financial results on November 7, 2024, before the market opens. Following this release, the company's management will conduct a webcast at 8:00 a.m. ET to discuss the results and provide updates on the business. Investors can access the webcast live or listen to a replay available on the company's website for 90 days.
Read more →ESPR▲ +13%on this news· ran to +27% by day 3
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
Esperion's European partner, Daiichi Sankyo Europe, reported positive results from the MILOS study, highlighting a substantial increase in patients achieving LDL-C goals with bempedoic acid. The study included data from 973 patients, showing a 30.3% mean reduction in LDL-C levels and a notable improvement from 4.9% to 35.3% in patients reaching their LDL-C targets after two years. These findings reinforce the role of bempedoic acid as an effective therapeutic option for managing cholesterol levels in at-risk populations.
Read more →ESPREsperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Esperion announced the granting of 3,500 restricted stock units (RSUs) to a new employee under its 2017 Inducement Equity Incentive Plan. This plan is specifically designed to attract individuals who were not previously associated with the company, promoting talent acquisition. The RSUs will vest partially after one year and then in quarterly installments over the following three years, contingent on the employee's ongoing employment with Esperion.
Read more →ESPR▼ -5.5%on this news
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
Esperion (NASDAQ: ESPR) has announced its participation in the 2024 Cantor Global Healthcare Conference scheduled for September 19, 2024. The event will feature a live webcast accessible via the company's website, with a replay available shortly after. This engagement represents a chance for Esperion to connect with investors and showcase its developments in the healthcare sector.
Read more →ESPREsperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe)
Esperion has announced that its products NEXLETOL and NEXLIZET have received additional coverage on various insurance formularies, enhancing access to over 136 million commercially insured and 34 million Medicare lives. The expanded coverage makes prescribing these FDA-approved medications easier for healthcare providers, particularly in managing LDL cholesterol in patients with specific cardiovascular conditions. While the medications have shown positive reception from payers, potential adverse effects like tendon ruptures and hyperuricemia must be monitored closely.
Read more →ESPREsperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
Esperion announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference scheduled for September 9, 2024. The company will host a live webcast at 8:30 a.m. ET, which can be accessed through their website. A replay of the webcast will be available two hours post-event and archived for 90 days.
Read more →ESPR▼ -8.9%on this news
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
Esperion announced strong second quarter 2024 financial results with a significant total revenue increase of 186% year-over-year. The company achieved $73.8 million in total revenue, along with notable growth in U.S. net product revenue driven by retail prescription increases. A major highlight was the successful monetization of European royalties for $304.7 million, which facilitated the early payoff of a secured facility. Despite positive strides, they faced a one-time financial loss associated with this transaction.
Read more →ESPREsperion to Report Second Quarter 2024 Financial Results on August 12
Esperion announced that it will release its financial results for the second quarter of 2024 on August 12, 2024, before the market opens. The management plans to host a webcast at 8:00 a.m. ET on the same day to discuss the results and provide business updates. Access to the live audio webcast and its replay will be available on the company's investor relations website.
Read more →ESPREsperion to Participate in Upcoming BTIG Biotech Conference
Esperion Therapeutics has announced its participation in the BTIG Biotech Conference scheduled for August 5, 2024, at 4 p.m. ET. This opportunity allows Esperion to showcase its latest developments and engage with potential investors. Participation in well-known industry events typically indicates a commitment to transparency and investor relations.
Read more →ESPREsperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility - OMERS Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products f
Esperion has announced a Royalty Purchase Agreement with OMERS Life Sciences, through which it will receive approximately $304.7 million for its royalty entitlement on bempedoic acid products. The agreement provides Esperion with enhanced operational and financial flexibility, allowing it to pay off existing revenue interest facilities. Future royalties from the European sales will revert to Esperion after OMERS recoups its investment. This transaction is expected to support Esperion's initiatives in U.S. market commercialization and further strengthen its financial position.
Read more →ESPREsperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL and NEXLIZET
Esperion has received a five-year patent extension for bempedoic acid, integral to its products NEXLETOL and NEXLIZET, extending the patent until December 3, 2030. This extension was granted by the U.S. Patent and Trademark Office under provisions that aim to encourage pharmaceutical innovation. NEXLETOL and NEXLIZET are crucial in lowering LDL cholesterol in patients who cannot use traditional statin therapies. The extended patent will be recorded in the FDA's Orange Book, indicating the drug's approved status and therapeutic equivalence.
Read more →ESPR▲ +11.8%on this newsshared move
Esperion Reports First Quarter 2024 Financial Results
Esperion Therapeutics reported a significant financial performance for Q1 2024, with total revenue reaching $137.7 million, reflecting a 467% year-over-year increase. The company received FDA approval for expanded indications of NEXLETOL and NEXLIZET, marking a critical development in their strategy to address a broader patient population at risk of cardiovascular issues. Notably, retail prescription equivalents also rose by 43% year-over-year. However, the increase in operating expenses, projected between $225 to $245 million, raises concerns about profitability despite robust revenue growth.
Read more →ESPREsperion to Participate in Upcoming May Investor Conferences
Esperion announced its participation in several investor conferences scheduled for May 2024. Notable events include the JMP Securities Life Sciences Conference in New York and the Bank of America Securities Health Care Conference in Las Vegas. These conferences will feature webcast access, allowing investors to engage with the company remotely. The archived webcasts will be available for 90 days post-event on their website.
Read more →ESPR▲ +9.4%on this news
Esperion to Report First Quarter 2024 Financial Results on May 7
Esperion announced that it will release its financial results for the first quarter of 2024 on May 7, 2024. The release will occur before market opening, followed by a management-hosted webcast at 8:00 a.m. ET. During this event, they plan to discuss the financial outcomes along with other business updates. Investors can participate by pre-registering for the conference call.
Read more →ESPR▼ -6.5%on this news· ran to -29% by day 3
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
Esperion presented new findings from the CLEAR Outcomes trial at ACC.24, highlighting the effectiveness of NEXLETOL in diverse patient populations, including women, Hispanic/Latinx individuals, and patients with obesity. Notably, patients with obesity who took NEXLETOL exhibited a 23% lower risk of significant cardiovascular events compared to those receiving a placebo. The trial's diversity is noteworthy, with nearly half of participants being women and a significant representation of Hispanic/Latinx patients, underscoring a commitment to inclusive health research. Despite its benefits, safety concerns such as hypersensitivity reactions and the risk of tendon injury were noted.
Read more →ESPREsperion to Ring Nasdaq Opening Bell Today, April 1, 2024
Esperion announced that President and CEO Sheldon Koenig will ring the Nasdaq opening bell to celebrate the FDA's approval of broad new labels for its products. This event highlights the company's progress in reducing prescribing limitations, ultimately enabling more patients to achieve management goals for LDL cholesterol. The ceremony will be live streamed and underscores the commitment of Esperion's team in reaching this milestone. The announcement triggers positive sentiments about the company's future in cardiovascular health management.
Read more →ESPREsperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
Esperion announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. The company's President and CEO, Sheldon Koenig, will partake in a fireside chat on April 9, 2024. Additionally, the Esperion management team is set to host investor meetings on the same day, emphasizing the company's commitment to engaging with investors. A live audio webcast of the events will be available through the Esperion website, ensuring broader access to the discussions.
Read more →ESPR▲ +14.4%on this newsshared move
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
Esperion has announced that three subgroup analyses from its CLEAR Outcomes trial will be presented at the 2024 American College of Cardiology's Annual Scientific Session (ACC.24) in Atlanta. The presentations will focus on statin-intolerant women and Hispanic/Latinx patients, showcasing the company’s dedication to addressing cardiovascular care in underserved populations. Additionally, the company will host a moderated session and an industry expert theatre, further underscoring its engagement with healthcare professionals.
Read more →ESPR▲ +10.3%on this news
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
Esperion reported strong financial results for Q4 and the full year 2023, with significant increases in both U.S. net product revenue and total revenue. The company resolved a key litigation, resulting in a $125 million cash inflow and substantial cost savings. Esperion is on track for regulatory approvals in early 2024 that could greatly enhance its product offerings for cardiovascular risk reduction. Despite the positive outlook, the company continues to face significant net losses and increasing operating expenses.
Read more →ESPREsperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
Esperion (NASDAQ: ESPR) announced the upcoming release of its fourth quarter and full year 2023 financial results on February 27, 2024. Following the results, a management-hosted webcast will take place at 8:00 a.m. ET to discuss the findings and provide updates on business activities. Interested participants are given options to pre-register for access and will also have the opportunity to listen to a replay of the webcast afterward.
Read more →ESPREsperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Esperion Therapeutics has successfully closed its public offering of 65,205,000 shares of common stock, including additional shares requested by underwriters, totaling gross proceeds of approximately $97.8 million. The company intends to utilize these funds for the commercialization of its cardiovascular drugs, NEXLETOL and NEXLIZET, and to support ongoing research and development efforts. Jefferies LLC served as the sole book-running manager for the offering, which follows regulatory approval from the SEC.
Read more →ESPR▼ -6%on this newsshared move
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
Esperion Therapeutics has announced the pricing of a public offering of 56.7 million shares at $1.50 per share, aiming to raise approximately $85.1 million. The funds are intended to support the commercialization of its drugs NEXLETOL and NEXLIZET, along with other corporate needs. The offering is expected to close on January 23, 2024, subject to customary conditions. In addition, the underwriters have the option to purchase up to 8.5 million additional shares. The company has acknowledged risks related to market conditions and the execution of the offering.
Read more →ESPR▼ -21.2%on this news
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
Esperion Therapeutics and Daiichi Sankyo Europe have announced a $125 million amendment to their collaboration, which includes a resolution to pending litigation. Esperion will receive an upfront payment of $100 million, with an additional $25 million payment following the European Medicines Agency's approval of their products. The companies plan to expand their collaboration, including the potential development of a new combination therapy aimed at high cholesterol. This settlement is expected to enhance long-term value for both parties and streamline their manufacturing and supply operations.
Read more →ESPR▲ +15.9%on this news· ran to +29% by day 1
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference, where CEO Sheldon Koenig will deliver a corporate presentation. Scheduled for January 10, 2024, at 2:15 PM PT, this event is an opportunity for Esperion to connect with investors. Additionally, the management team will host investor meetings during the conference, indicating an active effort to engage with stakeholders.
Read more →ESPREsperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
Esperion presented results from the CLEAR Outcomes trial at the AHA Scientific Sessions 2023, showcasing that bempedoic acid can significantly reduce vascular inflammation, particularly in patients intolerant to statins. The analysis indicated that higher baseline inflammation correlated with increased major cardiovascular events and mortality rates. Importantly, bempedoic acid achieved a 21.6% reduction in the inflammatory marker hsCRP compared to placebo. However, the long-term effects on cardiovascular health remain undetermined, and patients should be aware of potential serious side effects associated with the drug.
Read more →ESPR▲ +7.7%on this newsshared move
Esperion Reports Third Quarter 2023 Financial Results
Esperion reported strong financial results for Q3 2023, highlighting a 45% growth in U.S. net product revenue and an overall revenue increase of 79% year-over-year. The company received FDA acceptance for expanded indications for its products, expecting approval by March 31, 2024. Moreover, positive outcomes from clinical trials were presented, demonstrating the efficacy of NEXLETOL and NEXLIZET in reducing cardiovascular risks. Despite net losses, the reduced amount indicates better cost management and outlook for future revenue growth.
Read more →ESPREsperion to Participate in Jefferies London Healthcare Conference
Esperion Therapeutics announced its participation in the Jefferies London Healthcare Conference, scheduled for November 14, 2023. CEO Sheldon Koenig will engage in a fireside chat during the event. Additionally, the company plans to host investor meetings that same day. The event will be accessible via a live audio webcast, with a replay available on their website for 90 days.
Read more →ESPREsperion to Report Third Quarter 2023 Financial Results on November 7
Esperion Therapeutics has announced that it will release its financial results for the third quarter of 2023 on November 7. The release will be followed by a management-hosted webcast where they will discuss the results and provide updates on business operations. Interested participants can pre-register for the conference call through the company’s website, enhancing accessibility for investors and analysts.
Read more →ESPR▲ +14.5%on this news
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. The company's President and CEO, Sheldon Koenig, will give a corporate presentation on September 11, 2023. Additionally, the management team will hold investor meetings on the same day. A live audio webcast of the presentation will be available through the company's website.
Read more →ESPR▲ +14.5%on this newsshared move
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
Esperion presented results from two late-breaking studies on bempedoic acid at the ESC 2023 Congress, highlighting its effectiveness in reducing cardiovascular events in high-risk patients. The results showed significant risk reductions in major adverse cardiovascular events (MACE) without increasing the incidence of new onset diabetes. Encouragingly, bempedoic acid can provide benefits for patients who cannot tolerate statins. However, potential side effects, including tendon rupture, have been noted, necessitating careful monitoring.
Read more →ESPR▲ +7.6%on this news
Esperion Reports Second Quarter 2023 Financial Results
Esperion reported strong financial results for Q2 2023, with a 49% increase in U.S. net product revenue to $20.3 million. The company has submitted applications for expanded indications in the U.S. and Europe, aiming for approvals in the first half of 2024. New data from their CLEAR Outcomes analysis showed significant cardiovascular risk reduction with bempedoic acid, potentially expanding their market reach significantly. However, the company continues to face financial challenges, reporting net losses of nearly $50 million for the quarter.
Read more →ESPREsperion to Participate in BTIG Virtual Biotechnology Conference 2023
Esperion Therapeutics, listed on NASDAQ as ESPR, announced its participation in the upcoming BTIG Virtual Biotechnology Conference 2023. The Chief Financial Officer, Ben Halladay, is scheduled to engage in a fireside chat on August 7, 2023, at 9:00 AM ET. In addition to the chat, the management team will be hosting investor meetings on the same day, facilitating direct dialogue with stakeholders.
Read more →ESPREsperion to Report Second Quarter 2023 Financial Results on August 1
Esperion announced that it will report its second quarter financial results on August 1, 2023, before the market opens. Following the release, the company's management will hold a webcast at 8:00 a.m. ET to discuss the results and provide updates on business activities. Interested participants have the option to pre-register for the conference call.
Read more →ESPREsperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
Esperion Therapeutics announced the upcoming presentation of an abstract at the 2023 ASPC Congress on cardiovascular disease (CVD) prevention. The study focuses on the background ezetimibe use among participants in the CLEAR Outcomes trial. This trial is part of a larger research initiative assessing the safety and efficacy of NEXLETOL and NEXLIZET, which aim to meet significant unmet medical needs in CVD. The event will include several sessions for presentation and Q&A, allowing for in-depth discussion of the data.
Read more →ESPREsperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO (bempedoic acid) Tablet and NUSTENDI (bempedoic acid and ezetimibe) Tablet
Esperion has submitted an application to the European Medicines Agency (EMA) seeking expanded indications for its products NILEMDO and NUSTENDI for cardiovascular risk reduction in patients. This follows promising results from the CLEAR Outcomes trial, showing significant reductions in various cardiovascular events. The company anticipates a decision from the EMA by October 2023 and potential approvals in 2024, paralleling similar submissions made to the FDA. Despite the positive trajectory, the application carries inherent risks, including safety concerns related to both treatments.
Read more →ESPREsperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83 rd American Diabetes Association Scientific Sessions - 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and 25% r
Esperion announced significant results from its CLEAR Outcomes primary prevention analysis at the American Diabetes Association Scientific Sessions. The analysis showed a 30% reduction in MACE-4 composite events among statin-intolerant patients. Bempedoic acid, the first LDL-lowering therapy to demonstrate cardiovascular risk reduction in such a population, presents a promising treatment option for an estimated 70 million individuals at risk for cardiovascular events. The findings were published in the Journal of the American Medical Association, highlighting the potential clinical impact of bempedoic acid on primary prevention strategies.
Read more →ESPR▲ +11.4%on this news
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Esperion has presented new analysis results on bempedoic acid treatment at ENDO 2023, indicating that its cardiovascular risk reduction benefits are comparable to those of statins based on LDL-C reduction. The analysis was conducted with data from the CLEAR Outcomes study, focusing on statin-intolerant patients. Key reductions in major adverse cardiovascular events were reported, showcasing the potential importance of bempedoic acid for patients who are unable to tolerate statins. However, safety issues, including risks of hyperuricemia and tendon rupture, must be carefully considered.
Read more →ESPREsperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
Esperion Therapeutics announced that it will present significant findings at the American Diabetes Association's 83rd Scientific Sessions from June 23-26, 2023, in San Diego. The presentations will include a late-breaking poster session and an oral presentation focused on LDL cholesterol reduction and cardiovascular outcomes in high-risk primary prevention patients. The data is part of the CLEAR clinical research program aimed at validating the efficacy and safety of bempedoic acid, a novel treatment for cardiovascular disease. The program is notable for involving over 60,000 participants and is expected to enhance treatment approaches for millions with elevated LDL cholesterol.
Read more →ESPREsperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
Esperion Therapeutics announced that it will present additional analyses from the CLEAR Outcomes Study at the upcoming ENDO 2023 conference. The presentation will focus on the cardiovascular benefits of bempedoic acid compared to statins. This follows a comprehensive research program designed to explore the safety and efficacy of bempedoic acid, which has the potential to benefit millions. The study is part of a broader initiative aimed at addressing unmet medical needs in cardiovascular health.
Read more →ESPREsperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet
Esperion has submitted Supplemental New Drug Applications (sNDA) to the FDA for its products NEXLETOL and NEXLIZET, aiming to include cardiovascular risk reduction and expand LDL-C lowering indications. The submissions are based on promising outcomes from the CLEAR Outcomes trial, which has shown significant reductions in cardiovascular events. The company expects potential approval from the FDA in the first half of 2024, which could enhance adoption among healthcare providers and patients. However, the applications also highlight the absence of definitive evidence on the impact of these drugs on long-term cardiovascular outcomes.
Read more →ESPR▼ -5.7%on this news
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
Esperion has announced that its 2023 Annual Meeting of Stockholders has been adjourned and will reconvene virtually on June 15, 2023. This decision was made to provide stockholders with more time to vote on the proposals outlined in the Proxy Statement. So far, an overwhelming majority of those who voted support the Board's recommendations, though more votes are still needed to move forward with the proposals. Stockholders are encouraged to participate in the upcoming meeting.
Read more →ESPREsperion to Participate in Jefferies Healthcare Conference
Esperion announced that its CEO, Sheldon Koenig, will participate in a fireside chat at the Jefferies Healthcare Conference on June 7, 2023. The participation signifies the company's engagement with the healthcare investment community. Additionally, the management team will be available for individual investor meetings, providing further opportunities for dialogue and investment discussions.
Read more →ESPR▲ +5.2%on this newsshared move
Esperion Reports First Quarter 2023 Financial Results
Esperion reported a 27% year-over-year increase in U.S. net product revenue to $17 million for the first quarter of 2023. The company highlighted the significance of its CLEAR Outcomes trial data, which confirmed cardiovascular benefits from bempedoic acid, driving public interest and prescription growth. A commercial partnership with Currax Pharmaceuticals was established to enhance marketing efforts. However, the net loss for the quarter rose to $61.7 million, despite revenue gains, and R&D costs increased significantly.
Read more →ESPREsperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
Esperion has retained the law firm Gibson Dunn to pursue a $300 million milestone payment from Daiichi Sankyo Europe, which has declared it will not pay. The company’s amended complaint cites new evidence that supports Esperion's claims regarding its contractual rights and contends that DSE is acting in bad faith. Esperion expects to receive the payment upon regulatory approval in the first half of 2024. The company's upcoming earnings call on May 9 will provide further updates on financial performance.
Read more →ESPR▲ +7.6%on this newsshared move
Esperion to Participate in JMP Securities Life Sciences Conference
Esperion announced that its CEO, Sheldon Koenig, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 15, 2023. This event aims to enhance engagement with investors and stakeholders. The company will provide access to a live audio webcast, which will be archived for 90 days following the event. This initiative reflects Esperion's commitment to transparency and communication within the life sciences sector.
Read more →ESPREsperion to Participate in Bank of America Securities 2023 Health Care Conference
Esperion (NASDAQ: ESPR) has announced that CEO Sheldon Koenig will host a fireside chat at the Bank of America Securities 2023 Health Care Conference on May 11, 2023. The event is designed to present the company's strategic insights and foster engagement with stakeholders. A live audio webcast of the event will be accessible via Esperion's investor relations website, with a replay available for 90 days after the call.
Read more →ESPREsperion to Report First Quarter 2023 Financial Results May 9, 2023
Esperion announced it will report its first quarter 2023 financial results on May 9, 2023, before the U.S. financial markets open. The company will host a webcast at 8:00 a.m. ET to discuss these results and progress in its business operations. Investors have the option to pre-register for the conference call and access the replay, which will be available for around 90 days on the company's website.
Read more →ESPREsperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
Esperion has entered a co-promotion agreement with Currax Pharmaceuticals LLC, allowing Currax's 72 sales representatives to promote the company's cholesterol-lowering drugs, NEXLETOL and NEXLIZET. This strategic partnership is aimed at boosting the sales and visibility of Esperion's products by significantly increasing the sales force. The collaboration is expected to enhance awareness and usage of these medications, particularly following positive outcomes from the CLEAR Outcomes trial that evaluated NEXLETOL's effectiveness in reducing cardiovascular events. Esperion's leadership expressed optimism about the growth potential resulting from this agreement.
Read more →ESPREsperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
Esperion announced that its CEO, Sheldon Koenig, will host a fireside chat at the Needham 22nd Annual Virtual Healthcare Conference scheduled for April 17th, 2023. This event aims to provide insights into the company's operations and strategic direction. A live audio webcast of the conference will be available on Esperion's website, with a replay accessible for 90 days after the event.
Read more →ESPREsperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Esperion announced the successful closing of a registered direct offering worth $56.7 million, involving 33,170,747 shares of common stock alongside short-term warrants. Each share was sold at a price of $1.675, with warrants exercisable for three and a half years at an exercise price of $1.55 per share. The funds garnered from the offering will be allocated to general corporate purposes, indicating Esperion's strategy to bolster its operations and financial health.
Read more →ESPREsperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Esperion has announced a registered direct offering worth $56.7 million with healthcare-focused institutional investors. The offering includes the sale of approximately 33.2 million shares of common stock, combined with short-term warrants. The proceeds from this offering are intended for general corporate purposes, with the closing expected to occur around March 22, 2023. Additionally, existing warrants from December 2021 are being amended to reduce the exercise price and extend their term.
Read more →ESPR▼ -20%on this news
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary P
The CLEAR Outcomes Study presents significant findings regarding Esperion's NEXLETOL, indicating it reduces hard ischemic events in a diverse population of patients who cannot tolerate statin therapy. The study reveals that NEXLETOL lowered the risk of major adverse cardiovascular events by 13-15% and myocardial infarction risk by 23%. Results from this trial can lead to expanded treatment options and anticipated milestone payments for the company, while also being presented at a major cardiology conference. However, there are specific safety concerns associated with the treatment, particularly regarding tendon issues for some patients.
Read more →ESPR▲ +6.3%on this news
Esperion Launches New Scientific Website
Esperion has launched a new scientific website, esperionscience.com, aimed at the scientific and medical communities. The website provides detailed information about Esperion's CLEAR program, clinical trials, and updates on their pipeline related to cardiometabolic disease. The initiative emphasizes the company's commitment to advancing lipid lowering therapies and addressing unmet needs in cardiovascular health. The platform includes resources such as clinical trial abstracts, publications, and expert videos.
Read more →ESPREsperion to Participate in the Cowen 43rd Annual Healthcare Conference
Esperion announced that CEO Sheldon Koenig will present at the Cowen 43rd Annual Healthcare Conference on March 8, 2023. The event will provide an opportunity for Esperion to showcase their advancements in therapeutics. Interested parties can access a live webcast of the presentation, along with a replay that will be available for 90 days after the event.
Read more →ESPR▼ -5.6%on this newsshared move
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update - Landmark CLEAR Outcomes Trial Successfully Completed and Met the Major Adverse Cardiovascular Events (MACE-4) Primary End
Esperion reported its fourth quarter and full year 2022 financial results, highlighting a successful completion of the CLEAR Outcomes Trial, which met its primary endpoint. U.S. net sales for Q4 reached $15 million, up 23% year-over-year, with total sales for the year at $56 million, a 40% increase. The company also reduced its selling and administrative expenses significantly by 41%. However, despite these achievements, Esperion reported net losses of $55.5 million for the quarter and $233.7 million for the year.
Read more →ESPR▼ -5.6%on this newsshared move
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
Esperion has announced that its CLEAR Outcomes trial results, which demonstrate the effectiveness of NEXLETOL in reducing cardiovascular risk in statin-intolerant patients, will be presented as a late-breaking clinical trial at the upcoming ACC.23/WCC event. The company's president expressed enthusiasm for sharing detailed data, reflecting significant interest from the healthcare community. The results are particularly relevant for patients who have high cardiovascular risk but cannot tolerate statins. However, the safety profile of NEXLETOL includes warnings about hyperuricemia and tendon rupture risks.
Read more →ESPREsperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
Esperion announced plans to report its fourth quarter and full year 2022 financial results on February 21, 2023. The report will be released before U.S. markets open, followed by a conference call hosted by company management. During the call, the management will discuss the financial results and future milestones for the company. A live webcast will be available for investors and media, along with a replay of the call afterwards.
Read more →ESPR▲ +11%on this news
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results - Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates globa
Esperion has outlined its upcoming milestones and announced preliminary financial results for the fourth quarter of 2022. The company expects to submit regulatory packages based on the positive CLEAR Outcomes data in the first half of 2023, anticipating significant revenue growth. A new partnership with RFK Racing will focus on increasing consumer awareness regarding cholesterol management. Although growth is expected, the company cautions that its preliminary financial results are not final and may change.
Read more →ESPREsperion to Participate in January Investor Meetings
ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-person events are taking
Read more →ESPR▼ -14.9%on this news· ran to -28% by day 3
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint
– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint – – Presentation of comprehensive data
Read more →ESPREsperion Appoints Ben Halladay Chief Financial Officer
Esperion Appoints Ben Halladay Chief Financial ANN ARBOR, Mich., November 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Fin
Read more →ESPREsperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline, Planned Scientific Focus, and Future Growth Drivers – – Virtual Program Begins at 10a
Read more →ESPREsperion Reports Third Quarter 2022 Financial Results and Provides Company Update - CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion - - Remain On Track to Report Topline
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update - CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion - - Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be
Read more →ESPREsperion Hosting Virtual Research & Development Day
– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host a virtual research and developmen
Read more →ESPREsperion to Report Third Quarter 2022 Financial Results November 1, 2022
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, November 1st, 2022. Following the release, company management will host a web
Read more →ESPR▼ -5.8%on this newsshared move
Esperion Announces Bempedoic Acid (NEXLETOL ) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease
Read more →ESPR▲ +7.7%on this newsshared move
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update - Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial On Track for Topline Results 1Q 2023 - - U.S. Net P
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update - Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial On Track for Topline Results 1Q 2023 - - U.S. Net Product Revenue of NEXLETOL (bempedoic acid) Tablets and NE
Read more →ESPREsperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB represent a diverse group of internationally renowned experts who will bring a depth and
Read more →ESPREsperion to Report Second Quarter 2022 Financial Results August 2, 2022
ANN ARBOR, Mich., July 12, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, August 2, 2022. Following the release, company management will host a webca
Read more →ESPREsperion to Participate in the 2022 Jefferies Global Healthcare Conference
ANN ARBOR, Mich., June 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming 2022 Jefferies Global Healthcare Conference on June 8th, 2022. Event: 2022 Jefferies Global Healt
Read more →ESPRstatements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COV
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion's Board of Directors. Mr. Carroll will ser
Read more →ESPREsperion Announces the Appointment of J. Martin Carroll to its Board of Directors
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion’s Board of Directors. Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockh
Read more →ESPREsperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted abstracts showcase breadth of Esperion’s research into efficacy of bempedoic acid in patients with atherosclerotic cardiovas
Read more →ESPR▲ +10.7%on this news
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference on Tuesday, May 24th, 2022. Ev
Read more →ESPR▲ +14%on this news
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update - Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation- - U.S. Net Product Revenue of NEXLETOL (bempedoic acid) Tablets an
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update - Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation- - U.S. Net Product Revenue of NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets Grew app
Read more →ESPREsperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL®, in the American Journal of Cardiology. The paper, “Long-term Saf
Read more →ESPREsperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10th, 2022. Event: Bank of
Read more →ESPREsperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeti
Read more →ESPR▲ +8.8%on this newsshared move
Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET (bempedoic acid and ezetimibe) in Reducing LDL-Cholesterol Following a Recent Acute Coronary Syndrome Event
ANN ARBOR, Mich., April 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced support for a study to evaluate the effects of bempedoic acid and ezetimibe (NEXLIZET) on short-term LDL-cholesterol lowering in patients following a recent acute coronary syndrome (ACS)
Read more →ESPREsperion to Report First Quarter 2022 Financial Results May 3, 2022
ANN ARBOR, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, May 3, 2022. Following the release, company management will host a webcast
Read more →ESPR▲ +7.4%on this newsshared move
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
ANN ARBOR, Mich., April 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from a pooled analysis of patients enrolled in four Phase 3 bempedoic acid studies in the Journal of Clinical Lipidology. The paper, “Efficacy and safety of bempe
Read more →ESPR▲ +5.8%on this news
Esperion Announces Two NEXLETOL (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL®) at the American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22). The first ana
Read more →ESPREsperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., March 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Needham 21st Annual Healthcare Conference on Tuesday, April 12, 2022. Event: 21 st Annual Needham
Read more →ESPREsperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
ANN ARBOR, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Chief Medical Officer, Dr. JoAnne Foody, will participate in a Cardiometabolic/NASH focused panel, in addition to one-on-one investor meetings with other members of management, at the
Read more →ESPR▲ +13.5%on this newsshared move
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update - Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 - - U.S. Net Product Revenue of NEXLET
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update - Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 - - U.S. Net Product Revenue of NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid a
Read more →ESPREsperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
ANN ARBOR, Mich., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, February 22, 2022. Following the release, company management
Read more →ESPREsperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update - Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in
Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update - Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022 Achieved 85% MACE Accumulation in December - - Fo
Read more →ESPR▼ -8.2%on this newsshared move
Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference
ANN ARBOR, Mich., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming virtual J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. E
Read more →ESPREsperion Appoints Benjamin O. Looker as General Counsel - Addition to management team brings experienced strategic legal counsel as Company nears pivotal milestones - A
Esperion Appoints Benjamin O. Looker as General Counsel - Addition to management team brings experienced strategic legal counsel as Company nears pivotal milestones - ANN ARBOR, Mich., January 4, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ ESPR), today announced the appointment o
Read more →ESPREsperion Announces Closing of $225 Million Public Offering
ANN ARBOR, Mich., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the closing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and accompanying warrants to purchase an aggreg
Read more →ESPR▼ -41.5%on this newsshared move
Esperion Announces Pricing of $225 Million Public Offering
ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an ag
Read more →ESPR▲ +11.6%on this news· ran to -35% by day 1shared move
Esperion Announces Proposed Public Offering
Esperion Announces Proposed Public Offering ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) ("Esperion" or the "Company"), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or comm
Read more →ESPR▼ -5.1%on this news
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of patients - - In patients with metabolic syndrome NEXLETOL lowered hemoglobin A1c (Hb
Read more →ESPREsperion Reports Third Quarter 2021 Financial Results and Provides Company Update
– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR Outcomes Study Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achi
Read more →ESPRBen Church bchurch esperion.com 734-864-6774 Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update - Recently Announced Transformative Plan to Align Operational and Expense Structure t
bchurch esperion.com Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update - Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth - - Unprecedented CLEAR Outco
Read more →ESPR▲ +13.1%on this newsshared move
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021. AHA Scientific Sessions 2021 On Demand Session
Read more →ESPR▲ +13.1%on this newsshared move
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board ANN ARBOR, Mich., November 1, 2021 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting "On behalf
Read more →ESPR▲ +6.9%on this news· ran to +27% by day 3shared move
Esperion to Participate in Upcoming Virtual Investor Conference
ANN ARBOR, Mich., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that members of Esperion’s management team will participate in the upcoming Credit Suisse 30th Annual Healthcare Conference. Event: Credit Suisse 30 th Annual Healthcare Conference Date:
Read more →ESPR▼ -11.4%on this newsshared move
ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock
ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock ANN ARBOR, Mich., October 25, 2021 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) today announced that it has entered into a privat
Read more →ESPRESPERION Announces Plan for Transformative Long-Term Growth -Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes
ESPERION Announces Plan for Transformative Long-Term organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial- overall workforce by 40 percent and further shifts marketing strateg
Read more →ESPREsperion to Report Third Quarter 2021 Financial Results November 2, 2021
ANN ARBOR, Mich., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, November 2, 2021. Following the release, company management will host a webc
Read more →ESPRESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
ANN ARBOR, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future directions in the treatment of elevated cholesterol on Monday, September 13, 2021
Read more →ESPRKaitlyn Brosco ESPERION corporateteam esperion.com ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update - U.S. Net Product Revenue of NEXLETOL (bempedoic acid) Tablets and NEXLIZET (
corporateteam esperion.com ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update - U.S. Net Product Revenue of NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million - - Growth D
Read more →ESPRESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
– U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million – – Growth Driven by Increase in Demand and Substantial Improvement in Net Price – – Prescriptions Grew 28% During the Qu
Read more →ESPREsperion to Report Second Quarter 2021 Financial Results August 3, 2021
ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021. Following the release, company management will host a webca
Read more →ESPRESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer - Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline - ANN ARBOR, Mich., June 28, 2021 (GLOBE NEW
Read more →ESPREsperion to Participate in Two Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., May 24, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of June. Event: Jefferies Virtual Healthcare Conference Date: June 1, 2021 Form
Read more →ESPRESPERION Appoints Sheldon Koenig as President and CEO -- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO -- -- Suc
ESPERION Appoints Sheldon Koenig as President has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as -- Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to
Read more →ESPRKaitlyn Brosco ESPERION corporateteam esperion.com ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update - U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Pric
corporateteam esperion.com ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update - U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price - - Prescriptions Grew 46% Sequentially More Than 35,000 Patients now on NEXLETOL (bemp
Read more →ESPRESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets – – Secured Major Medicare Part D C
Read more →ESPREsperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL (bempedoic acid) Tablet in American Heart Journal
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy – – Nearly half of trial participants are women, a significantly higher proportion than have been included in any other previous cardiova
Read more →ESPRBen Church Esperion corporateteam esperion.com Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories - Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Pa
corporateteam esperion.com Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories - Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Payments - - Milestones from Partnership with Daiichi Sankyo Group Now Total Up to $1.1
Read more →ESPREsperion Secures $50 Million Funding from Oberland Capital
ANN ARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced that an investor group led by Oberland Capital Management LLC (Oberland Capital) agreed to provide the third and final tranche of funding under the revenue-based funding agre
Read more →ESPREsperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
– Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Payments – – Milestones from Partnership with Daiichi Sankyo Group Now Total Up to $1.1 Billion – – Demonstrates Daiichi Sankyo Group’s Commitment to the Bempedoic Acid Franchise and Strength o
Read more →ESPREsperion to Report First Quarter 2021 Financial Results May 4, 2021
ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesday, May 4, 2021. Following the release, company management will host a webcast
Read more →ESPREsperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 1
Read more →ESPRESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes Study Design Highlighted
Read more →ESPRKaitlyn Brosco ESPERION corporateteam esperion.com ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update - Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Appr
corporateteam esperion.com ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update -Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter - -Over 21,000 Patients on NE
Read more →ESPREsperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Tuesday, February 23, 2021. Following the release, company management
Read more →ESPRKaitlyn Brosco ESPERION corporateteam esperion.com ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program - Fourth-quarter
corporateteam esperion.com ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program - Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million - - Range represent
Read more →ESPRESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million – – Range represents over 140 percent sequential growth for NEXLETOL® (bempedoic acid) tablets and NEXLIZET® (bempedoic acid and ezetimibe) tablets – – Company provides full-year 2021 operati
Read more →ESPREsperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 7:30 a.m. Eastern
Read more →ESPRFALSE000143486800014348682020-12-162020-12-16
FALSE000143486800014348682020-12-162020-12-16 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 16, 2020 Esperion Therapeutics, Inc. (Ex
Read more →ESPRBen Church ESPERION bchurch esperion.com 734-864-6774 ESPERION Appoints Sheldon Koenig as Chief Operating Officer
bchurch esperion.com ESPERION Appoints Sheldon Koenig as Chief Operating Officer ANN ARBOR, Mich., December 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating of
Read more →ESPRESPERION Appoints Sheldon Koenig as Chief Operating Officer
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating officer, effective today. Koenig will report directly to Tim M. Mayleben, president and
Read more →ESPREsperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes
ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified instituti
Read more →ESPREsperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes ANN ARBOR, Mich., November 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million
Read more →ESPRESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
– Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets – – U.S. Product Revenue Increased Five-fold During the Third Quarter – – ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO™ (bemp
Read more →ESPRKaitlyn Brosco ESPERION investorrelations esperion.com ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update - Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL (bem
investorrelations esperion.com ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update -Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets - -U.S. Product Revenue I
Read more →ESPREsperion to Participate in Three Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in three upcoming virtual conferences during the month of November. Event: Credit Suisse 29 th Annual Virtual Healthcare Conference
Read more →ESPREsperion to Report Third Quarter 2020 Financial Results November 2, 2020
ANN ARBOR, Mich., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2020 financial results after the close of the U.S. financial markets on Monday, November 2, 2020. Following the release, company management will host a webca
Read more →ESPREsperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of NEXLETOL® (bempedoic acid) Tablets and the never-ending patien
Read more →ESPREsperion Announces Two Data Presentations of NEXLETOL (bempedoic acid) Tablet at the ESC Congress 2020
ANN ARBOR, Mich., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will present a pooled analysis from four Phase 3 clinical trials of NEXLETOL® (bempedoic acid) tablets as well as long-term safety and efficacy data from the CLEAR Harmony open-labe
Read more →ESPREsperion Reports Second Quarter 2020 Financial Results and Provides Company Update
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality Managed Care Coverage with Over 80% Commercial and Over 50% Medicare Part D Formu
Read more →ESPRBen Church Esperion 734-864-6774 bchurch@esperion.com Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update - Highest Quarterly and First Half Total Revenue in Company History with $
bchurch@esperion.com Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue - Capital Position with over $300 Million in Cash - High-Quality Managed C
Read more →ESPREsperion to Report Second Quarter 2020 Financial Results August 10, 2020
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on August 10, 2020. Following the release, company management will host a webcast and con
Read more →ESPREsperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL (bempedoic acid) Tablets
ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine, was published in the Journal of the American Medica
Read more →ESPREsperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
Esperion to Receive $150 Million Milestone Payment in June Esperion Completes Transfer of Marketing Authorization Approvals (MAAs) for NILEMDO™ (bempedoic acid) and NUSTENDI™ (bempedoic acid and ezetimibe) Tablets to DSE DSE to Initiate Commercial Rollout of NILEMDO and NUSTEND
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Ben Church Esperion 734-864-6774 bchurch@esperion.com Esperion and Daiichi Sankyo Europe Announce Amendment to License and Comme
aschwartz@esperion.com bchurch@esperion.com Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement ANN ARBOR, Mich., June 22, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced the completion of an amendment to the EU
Read more →ESPREsperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions
ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American Diabetes Association 80th Scientific Sessions. According to the American Diabetes Associ
Read more →ESPREsperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER
ANN ARBOR, Mich., June 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today confirms it has received notice that the Institute of Clinical and Economic Review (ICER) plans to assess new non-statin medicines for hypercholesterolemia in the U.S., including the clinical cost e
Read more →ESPREsperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, Jun
Read more →ESPREsperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers – – Launch Date Acc
Read more →ESPREsperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
ANN ARBOR, Mich., May 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference 2020 on Tuesday, June 2,
Read more →ESPREsperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA Securities 2020 Healthcare Conference on Tuesday, May 12, 2020, at
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Ben Church Esperion 734-864-6774 bchurch@esperion.com Esperion Reports First Quarter 2020 Financial Results and Provides Company
aschwartz@esperion.com bchurch@esperion.com Esperion Reports First Quarter 2020 Financial Results and Provides Company Update - Company Secures Marketing Approvals for NEXLETOL and NEXLIZET Tablets in the U.S. as well as for NILEMDO and NUSTENDI Tablets in Europe - - NEXLETO
Read more →ESPREsperion Reports First Quarter 2020 Financial Results and Provides Company Update
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in Europe NEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March 30th NEXLIZET™ (bempedoic acid and ezetimibe) Tablets Comme
Read more →ESPREsperion to Report First Quarter 2020 Financial Results May 6, 2020
ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following the release, company management will host a webcast and confere
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Ben Church Esperion 734-864-6774 bchurch@esperion.com Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Deve
aschwartz@esperion.com bchurch@esperion.com Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic ANN ARBOR, Mich., Apr. 20, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESP
Read more →ESPREsperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
– Esperion to Receive $60 Million Upfront Payment – – Up to $510 Million in Total Milestones – – Substantial Tiered Royalties – – Combines Esperion’s Expertise in Lipid Management with Otsuka’s Deep Cardiovascular Drug Development and Commercialization Expertise in Japa
Read more →ESPREsperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., April 09, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Ben Church Esperion 734-864-6774 bchurch@esperion.com Esperion Announces European Commission Approval of the NILEMDO (bempedoic
aschwartz@esperion.com bchurch@esperion.com European Commission Approval of the NILEMDO (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indic
Read more →ESPREsperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
– First Non-Statin, LDL-C Lowering Combination Medicine Ever Approved in Europe – – NUSTENDI Is Approved for Patients Who Require Additional LDL-Cholesterol Lowering on a Background Statin, Other Lipid-Lowering Therapies, or Considered Statin Intolerant – – Daiichi Sankyo Europ
Read more →ESPREsperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option – – Esperion Aims to Set New Industry Standard by Pricing NEXLETOL for Patient Affordability and Access – – Company Repurposes Heal
Read more →ESPRESPERION April 2020 CORPORATE OVERVIEW SAFE HARBOR FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, inc
Co-Principal Investigators : A. Michael Lincoff M.D., Cleveland Clinic, and Stephen Nicholls M.D., Monash University in Melbourne. A randomized, double-blind, placebo controlled study to assess the effects of NEXLETOL on the occurrence of major cardiovascular events in patients w
Read more →ESPREsperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET were presented at the American College of Cardiology’s 69th
Read more →ESPREsperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET will be presented at the American College of Cardiology’s 6
Read more →ESPREsperion Announces the Appointment of Alan Fuhrman to its Board of Directors
ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very pl
Read more →ESPREsperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that the company will participate in fireside chats at the following conferences: Cowen 40th Annual Health Care Conference in Boston Monday, March 2, 2020 11:20 AM EST Barclays Global H
Read more →ESPREsperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31, 2019. “2019 was a precedent setting year for our Lipid Management Team highlighte
Read more →ESPREsperion Announces FDA Approval of the NEXLIZET (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Esperion Announces FDA Approval of the NEXLIZET (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins - LDL-Cholesterol Lowering Combination
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Ben Church Esperion 734-864-6774 bchurch@esperion.com Media Contact: Elliot Fox W2Opure 212-257-6724 efox@purecommunications.com
aschwartz@esperion.com bchurch@esperion.com efox@purecommunications.com Esperion Announces FDA Approval of NEXLETOL (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol - First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in th
Read more →ESPREsperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients – – NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism – – Fills an Unmet Need for Affordable Medicines for Millions of Patients w
Read more →ESPREsperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
– Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism – – Positive CHMP Opinion is Based on the Completed Pivotal Phase 3 Fixed Dose Combination Tablet LDL-Cholesterol
Read more →ESPREsperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2020 at 12:00 p
Read more →ESPREsperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia. Bempedoic acid is bein
Read more →ESPREsperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
– Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – – Over 52-Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo – – Bempedoic Acid is being developed as an Oral, Once-daily ATP Citrate
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019. “The Esperion Lipid Management Team continues to lay a strong and
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Elliot Fox W2Opure 212-257-6724 efox@purecommunications.com Esperion Provides Bempedoic Acid Franchise Development Program Updat
aschwartz@esperion.com efox@purecommunications.com Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results ANN ARBOR, Mich., November 6, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid fra
Read more →ESPREsperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia on Sunday, November 17
Read more →ESPREsperion to Report Third Quarter 2019 Financial Results November 6, 2019
ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open. Bempedoic acid is our lead, non-statin, orally available, once-daily, low-densi
Read more →ESPREsperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial – – Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the completion
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Elliot Fox W2Opure 212-257-6724 efox@purecommunications.com Esperion Announces Positive Top-Line Results from Phase 2 Study of B
aschwartz@esperion.com efox@purecommunications.com Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering - 25
Read more →ESPREsperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
— Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering — — Provided 25% hsCRP Reduction — — No Worsening of Glycemic Control — — Overall Adverse Events Comparable to Placebo — — Conference Call and Webcast on Thursday, August 29 a
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019. “This year continues the momentum we’ve come to expect from our team o
Read more →ESPREsperion to Present at the BTIG Biotechnology Conference
ANN ARBOR, Mich., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology Conference in New York, NY on Monday, August 12, 2019 at 11:00 a.m. Eastern Time. Bem
Read more →ESPREsperion to Report Second Quarter 2019 Financial Results August 8, 2019
ANN ARBOR, Mich., July 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open. Bempedoic acid is our lead, non-statin, orally available, once-daily, LDL-C l
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Elliot Fox W2Opure 212-257-6724 efox@purecommunications.com Esperion and Oberland Capital Announce $200 Million Funding Agreemen
aschwartz@esperion.com efox@purecommunications.com Esperion and Oberland Capital Announce $200 Million Funding Agreement - $125 Million Upfront, $25 Million Upon FDA Approval, and $50 Million at Esperion s Option After Launch - - Initial Mid-Single Digit Repayment Rate on U.S
Read more →ESPREsperion and Oberland Capital Announce $200 Million Funding Agreement
- $125 Million Upfront, $25 Million Upon FDA Approval, and $50 Million at Esperion’s Option After Launch - - Initial Mid-Single Digit Repayment Rate on U.S. Revenue to Step Down to Less than One Percent Rate Upon Certain Revenue Achievements - - Esperion Reacquires 100% Revenue
Read more →ESPREsperion Announces the Appointment of Tracy M. Woody to Board of Directors
ANN ARBOR, Mich., May 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very plea
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
ANN ARBOR, Mich., May 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019. “The potential of bempedoic acid is being broadly realized as evidenced
Read more →ESPREsperion to Host Analyst and Investor Day Event on May 30
ANN ARBOR, Mich., May 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time. The event will feature presentations from members of the Esperion Lipid
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Elliot Fox W2Opure 212-257-6724 efox@purecommunications.com Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDA
aschwartz@esperion.com efox@purecommunications.com Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review Bempedoic Acid is an Oral, Once-daily ATP Ci
Read more →ESPREsperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
– Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver – – February 21, 2020 PDUFA Target Date Goal for Bempedoic Acid and February 26, 2020 PDUFA Target Date Goal for the Bempedoic Acid / Ezetimib
Read more →ESPREsperion to Present at the Needham & Company 18th Annual Healthcare Conference
ANN ARBOR, Mich., April 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipopr
Read more →ESPREsperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
– Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant – – Over 24-Weeks, Bempedoic Acid Was Observed to be Safe, Well-Tolerated, and the Muscle-Related Adverse Event Rate Did Not Differ from Placebo
Read more →ESPREsperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
–Study 2 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP– –Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Adverse Event Profile was Similar to that of Placebo– –Bempedoic Acid is an Oral, Once-daily ATP Citrate Lya
Read more →ESPREsperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
– Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – – Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher Overall Adverse Events Compared With Placebo – – Bempedoic Acid is an Oral, Once-d
Read more →ESPREsperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the results from Study 2 (1002-047, also known as CLEAR Wisdom, a pivotal Phase 3 study) of bempedoic acid will be presented in a late-breaking clinical trial session at the American
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Elliot Fox W2O Group 212-257-6724 efox@w2ogroup.com Esperion Provides Bempedoic Acid Franchise Development Program Updates; Repo
aschwartz@esperion.com Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipopro
Read more →ESPREsperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that the company has successfully completed important and key global marketing applications including the submission of two New Drug Applications (NDAs) for bempedoic acid and the bempedoi
Read more →ESPRInvestor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Elliot Fox W2O Group 212-257-6724 efox@w2ogroup.com Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commerciali
Investor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Media Contact: Elliot Fox W2O Group 212-257-6724 efox@w2ogroup.com Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe Esperion to Receive
Read more →ESPREsperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
– Esperion to Receive $300 Million in Upfront and Near-term Milestones – – Up to $900 Million in Total Milestones – – Substantial Tiered Royalties – – Esperion Partnering with a European CV Sales Organization Exceeding 1000 and One of the Most Succes
Read more →ESPREsperion to Present at the 37th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Michigan, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipo
Read more →ESPREsperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018
ANN ARBOR, Mich., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago. The late-breakin
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
ANN ARBOR, Mich., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipopro
Read more →ESPREsperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
– Phase 3 Program Achieved Safety and Tolerability Objectives – – Bempedoic Acid Achieved Additional 18% to 31% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% to 33% hsCRP Reduction – – 5-Component MACE Events in the Bempedoic Acid Arm wer
Read more →ESPREsperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid Study Met Safety and Tolerability Endpoints in 52-Week Study Bempedoic Acid Achieved Additional 18% LDL-C Lowering in Patien
Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid Study Met Safety and Tolerability Endpoints in 52-Week Study Bempedoic Acid Achieved Additional 18% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional
Read more →ESPREsperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study Bempedoic Acid / Ezetimibe Combo Pill Achieved an Additional 35% LDL-C Lowering in Patients on Maximally
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study Bempedoic Acid / Ezetimibe Combo Pill Achieved an Additional 35% LDL-C Lowering in Patients on Maximally Tolerated Statins 35% LDL-C Lowering Provides Potential f
Read more →ESPREsperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress
— Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background of Maximally Tolerated Statins — — Study 1 (CLEAR Harmony) Provided the Largest Evidence to Date that Bempedoic Acid Is Safe when Added on to Maximally Tolerated Statins — — Bempedoic Acid Provid
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
ANN ARBOR, Mich., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipopro
Read more →ESPREsperion to Host Analyst and Investor Day Event on July 10
ANN ARBOR, Mich., July 03, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipopro
Read more →ESPREsperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis
– Simultaneous Presentation of Full Data from 1st Phase 3 Study at ISA and Publication in the Journal Atherosclerosis – ANN ARBOR, Mich., June 12, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the full Phase 3 results from Study 4 (1002-048, also known as
Read more →ESPREsperion to Participate in Fireside Chat at the Jefferies 2018 Global Healthcare Conference
ANN ARBOR, Mich., May 30, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprot
Read more →ESPREsperion Announces the Appointment of Jay P. Shepard to Board of Directors
ANN ARBOR, Mich., May 29, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprot
Read more →ESPREsperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
— Study 3 Achieves Additional 26% LDL-C Lowering on Background of Maximally Tolerated LDL-C Lowering Therapy in Patients Considered Statin Intolerant — — Additional hsCRP Reduction of 25% — — Cumulative Phase 2 / Phase 3 Demonstrates Broad Efficacy as well as Safety and Tolerab
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Alex Schwartz Esperion 734-249-3386 aschwartz@esperion.com Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Prima
aschwartz@esperion.com Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint Study 3 Achieves Additional 26% LDL-C Lowering on Background of Maximally Tolerated LDL-C Lowering Therapy in Patients Considered Statin Intolerant Additional hsCRP
Read more →ESPREsperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
ANN ARBOR, Mich., May 22, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprot
Read more →ESPREsperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference
ANN ARBOR, Mich., May 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprot
Read more →ESPRExhib it 99.1 Study 1 Pivotal Phase (1002-040) 3 Long-Term Safety Study Supplemental Materials MAY 8, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-lookin
Study 1 Pivotal Phase (1002-040) 3 Long-Term Safety Study Supplemental Materials MAY 8, 2018 ODYSSEY Outcomes: Alirocumab LDL-C Lowering Wanes Over Time 103.1 Placebo ITT On-treatment* 105 90 75 60 45 30 15 0 101.4 66.4 Alirocumab ITT On-treatment* 53.3 0 4 8 12 16 20 24 28 32 3
Read more →ESPRESPERION INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Esperion Therapeutics, Inc. To Contact The Firm
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQ:ESPR) of the July 6, 2018 deadline to seek the role of lead plaintiff in a federal secur
Read more →ESPREsperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
ANN ARBOR, Mich., May 04, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprot
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results
ANN ARBOR, Mich., May 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprot
Read more →ESPREsperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
— Met Primary Endpoint of Safety and Tolerability in Largest and Longest Duration Study — — Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background Maximally Tolerated Statin Therapy — — Additional hsCRP Reduction of 22% on Background Maximally Tolerate
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Audrey Gross W20 Group 212.301.7214 agross@w2ogroup.com Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results Ann Arbor, Mich., (Globe Newswire May 2, 2018) Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, conv
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Audrey Gross W2O Group 212.301.7214 agross@w2ogroup.com Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Ac
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia Study Met Primary Endpoint with 30% Additional LDL-C Lowering hsCRP Reduction of 34% Observed to be Safe and Well-Tolerated in
Read more →ESPREsperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia
— Study Met Primary Endpoint with 30% Additional LDL-C Lowering — — hsCRP Reduction of 34% — — Observed to be Safe and Well-Tolerated in This Study — — Conference Call and Webcast on Tuesday, March 27, 2018, at 8:30 a.m. Eastern Daylight Time — ANN ARBOR, Mich., March 27, 201
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Audrey Gross W2O Group 212.301.7214 agross@w2ogroup.com Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study o
Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid Study 4 Met Primary Endpoint with 28% Additional LDL-C Lowering on Background Ezetimibe and Up to the Lowest Daily Dose of a Statin hsCRP Reduction of 33% Observed to be Safe and We
Read more →ESPREsperion to Participate in Fireside Chat at March 2018 Investor Conferences
ANN ARBOR, Mich., March 07, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipopr
Read more →ESPREsperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
— Study 4 Met Primary Endpoint with 28% Additional LDL-C Lowering on Background Ezetimibe and Up to the Lowest Daily Dose of a Statin — — hsCRP Reduction of 33% — — Observed to be Safe and Well-Tolerated in This Study — — Conference Call and Webcast on Wednesday, March 7, 2018
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
ANN ARBOR, Mich., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipopro
Read more →ESPREsperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
Fireside Chat Webcast on Wednesday, January 10, 2018 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time ANN ARBOR, Mich., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenie
Read more →ESPREsperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated
Read more →ESPREsperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference
ANN ARBOR, Mich., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated
Read more →ESPREsperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference
Fireside Chat Webcast on Tuesday, November 14, 2017 at 8:45 a.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-eff
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results
ANN ARBOR, Mich., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Provides Bempedoic Acid Franchise Development Program U
Esperion Therapeutics, Inc. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results Ann Arbor, Mich., (Globe Newswire November 7, 2017) Esperion Therapeutics, Inc. (NASDAQ: ESPR), the Lipid Management Company focused
Read more →ESPREsperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
– Top-Line Results Expected by the Fourth Quarter of 2018 – – NDA Submission for LDL-C Lowering Indication for the Bempedoic Acid / Ezetimibe Combination Pill Expected by First Quarter 2019 – ANN ARBOR, Mich., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDA
Read more →ESPREsperion to Host Analyst and Investor Day Event on October 17
ANN ARBOR, Mich., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated
Read more →ESPREsperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
– Pivotal Phase 3 Top-Line Results for Bempedoic Acid Expected in the Second and Third Quarters of 2018 – – NDA Submission for LDL-C Lowering Indication for Bempedoic Acid Planned by First Quarter 2019 – ANN ARBOR, Mich., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics,
Read more →ESPREsperion Prices Public Offering of Common Stock
ANN ARBOR, Mich., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Announces Proposed Public Offering of Common Stock Ann
Esperion Therapeutics, Inc. Esperion Announces Proposed Public Offering of Common Stock Ann Arbor, Mich., (Globe Newswire - August 8, 2017) Esperion Therapeutics, Inc. (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementa
Read more →ESPREsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
– Phase 3 Enrollment Progress Supports NDA Submissions for LDL-C Lowering Indications for Bempedoic Acid / Ezetimibe Combination Pill and Bempedoic Acid by the First Quarter 2019 – – Conference Call and Webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern Time – ANN ARBOR,
Read more →ESPREsperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
– 1002-038 Study Meets Primary Endpoint With a Robust 64% LDL-C Lowering Efficacy – – Clinically Relevant 48% hsCRP Reduction – – The Combination Therapy Was Observed to be Safe and Well-Tolerated – – Conference Call and Webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern
Read more →ESPREsperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results
– Conference Call and Webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern Time – ANN ARBOR, Mich., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, c
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid
Media Contact: Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor Ann Arbor, Mich., (Globe N
Read more →ESPREsperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
ANN ARBOR, Mich., July 26, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Announces FDA Confirmation of Regulatory Pathway to App
Esperion Therapeutics, Inc. Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significan
Read more →ESPREsperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
– Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of Muscle-Related Side Effects – – Bempedoic Acid / Ezetimibe Combination Program to be Conduct
Read more →ESPREsperion to Present at the JMP Securities 2017 Life Sciences Conference
Presentation and Webcast on Wednesday, June 21, 2017 at 10:00 a.m. Eastern Time ANN ARBOR, Mich., June 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-e
Read more →ESPREsperion to Present at the Jefferies 2017 Global Healthcare Conference
Presentation on Wednesday, June 7, 2017 at 10:30 a.m. Eastern Time ANN ARBOR, Mich., May 31, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once
Read more →ESPREsperion Provides Update on Common Stock Trading Activity
ANN ARBOR, Mich., May 22, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated l
Read more →ESPREsperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
Fireside Chat on Wednesday, May 17, 2017 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time ANN ARBOR, Mich., May 12, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementar
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Provides Bempedoic Acid Development Program Updates; Re
Esperion Therapeutics, Inc. Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results Ann Arbor, Mich., (Globe Newswire May 4, 2017) Esperion Therapeutics, Inc. (NASDAQ: ESPR), the Lipid Management Company focused on developing a
Read more →ESPREsperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
ANN ARBOR, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated l
Read more →ESPREsperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
Fireside Chat on Tuesday, April 4, 2017 at 1:40 p.m. Eastern Time ANN ARBOR, Mich., March 28, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective and
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Announces FDA Confirmation Regarding Regulatory Pathway
Media Contact: Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic
Read more →ESPREsperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those with ASCVD and/or HeFH - - On Track to Submit NDA for an LDL-C Lowering Indication b
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Announces Initiation of Phase 2 Triplet Oral Therapy St
Esperion Therapeutics, Inc. Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin Ann Arbor, Mich., (Globe Newswire March 7, 2017) Esperion Therapeutics, Inc. (NASDAQ: ESPR), the lipid management company focused on develop
Read more →ESPREsperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated
Read more →ESPREsperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session
Company to Host Webcast on Sunday, March 19, 2017 at 5:30 p.m. Eastern Time ANN ARBOR, Mich., March 06, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effe
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Provides Bempedoic Acid Development Program Update; Rep
Esperion Therapeutics, Inc. Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results Ann Arbor, Mich., (Globe Newswire February 22, 2017) Esperion Therapeutics, Inc. (NASDAQ: ESPR), the lipid management company foc
Read more →ESPREsperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results
ANN ARBOR, Mich., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated
Read more →ESPREsperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
Fireside Chat Webcast on Wednesday, February 22, 2017 at 8:00 a.m. Eastern Time ANN ARBOR, Mich., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-e
Read more →ESPREsperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia
Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016 Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD Risk Top-Line Results Expected by Q2 2018 ANN ARBOR, Mich., Jan. 25, 2017 (GLOBE NEWSWI
Read more →ESPREsperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Announces Initiation of Three Pivotal Phase 3 Studies f
Esperion Therapeutics, Inc. Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid Global Phase 3 Program Top-Line Results Expected Mid-2018 Ann Arbor, Mich., (Globe Newswire January 8, 2017) Esperion Therapeutics, Inc. (NASDAQ: ESPR), the lipid mana
Read more →ESPREsperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patie
Read more →ESPREsperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-
Read more →ESPREsperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
ANN ARBOR, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announce
Read more →ESPREsperion Therapeutics to Present at the Stifel 2016 Healthcare Conference
Presentation and Webcast on Wednesday, November 16, 2016 at 3:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment o
Read more →ESPRAudrey Gross W2O Group 212.301.7214 agross@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides Bempedoic Acid Development Pr
Media Contact: Audrey Gross W2O Group 212.301.7214 agross@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financi
Read more →ESPREsperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
ANN ARBOR, Mich., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided
Read more →ESPREsperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
Presentation and Webcast on Tuesday, November 8, 2016 at 3:00 p.m. Pacific Time/6:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Bempedoic Acid Global Phase 3 Clinical Program to Include Patien
Media Contact: Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose 1002-035 Study Meets Primary
Read more →ESPRElliot Fox W2O Group 12.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides Bempedoic Acid Development Program
Media Contact: Elliot Fox W2O Group 12.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial R
Read more →ESPREsperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
ANN ARBOR, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides Clinical Development and Regulato
Esperion Therapeutics, Inc. Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid On track to initiate global pivotal Phase 3 studies and CVOT in the fourth quarter Aligned with global regulatory authorities on a consistent definition of
Read more →ESPREsperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid
On track to initiate global pivotal Phase 3 studies and CVOT in the fourth quarter Aligned with global regulatory authorities on a consistent definition of statin intolerance Conference Call and Webcast on Tuesday, June 28, 2016 at 4:30 p.m. Eastern Time ANN ARBOR, Mich., June
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides Bempedoic Acid Development Progra
Esperion Therapeutics, Inc. Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results Ann Arbor, Mich., (Globe Newswire May 4, 2016) Esperion Therapeutics, Inc. (NASDAQ: ESPR), a pharmaceutical company focused on dev
Read more →ESPREsperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
ANN ARBOR, Mich., May 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with
Read more →ESPRESPERION 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
NEW ORLEANS, March 11, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 14, 2016 to file lead plaintiff applicat
Read more →ESPREsperion Therapeutics to Present at the Barclays Global Healthcare Conference
ANN ARBOR, Mich., March 08, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients wi
Read more →ESPREsperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results
ANN ARBOR, Mich., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients wit
Read more →ESPREsperion Therapeutics to Present at the 2016 RBC Capital Markets Global Healthcare Conference
ANN ARBOR, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients wit
Read more →ESPREsperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study
ANN ARBOR, Mich., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients wit
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Announces Initiation of Phase 2 Clinical S
Esperion Therapeutics, Inc. Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated with High-Dose Statin Therapy Ann Arbor, Mich., (Globe Newswire Jan. 12, 2016) Esperion Therapeutics, Inc. (NASDAQ: ESPR), a pharmaceutical com
Read more →ESPREsperion Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients wit
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides ETC-1002 Development Program Upda
Esperion Therapeutics, Inc. Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2015 Financial Results Ann Arbor, Mich., (Marketwired November 5, 2015) Esperion Therapeutics, Inc. (NASDAQ: ESPR), a pharmaceutical company focused on developi
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides Further Updates on ETC-1002 Globa
Esperion Therapeutics, Inc. Esperion Therapeutics Provides Further Updates on ETC-1002 Global Phase 3 Strategy Following Receipt of End-of-Phase 2 Meeting Minutes Conference Call and Webcast on Monday, September 28, 2015 at 5:00 p.m. Eastern Time Ann Arbor, Mich., (Marketwired
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Provides Update on The ETC-1002 Developmen
Esperion Therapeutics, Inc. Esperion Therapeutics Provides Update on The ETC-1002 Development Program Following End-of-Phase 2 Meeting with FDA Company on Track to Initiate Phase 3 Development Program in 2015 Conference Call and Webcast on Monday, August 17, 2015 at 4:30 p.m.
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Announces Positive Top-Line Phase 2 Result
Esperion Therapeutics, Inc. Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients with Hypercholesterolemia and Hypertension - ETC-1002-014 study meets primary endpoint - - LDL-cholesterol lowering significantly greater than placebo, with
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Announces Removal of 240 mg Partial Clinic
Esperion Therapeutics, Inc. Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC-1002 Ann Arbor, Mich., (July 7, 2015) Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-cl
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Barbara Ryan Clermont Partners 203.274.2825 bryan@esperion.com Esperion Therapeutics Provides ETC-1002 Development Program Update; Repo
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2015 Financial Results Conference Call and Webcast Today, May 7, 2015 at 4:30 p.m. Eastern Time Ann Arbor, Mich., (Marketwired May 7, 2015) Esperion Therapeutics, Inc. (NASDAQ: ESPR), an e
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Announces Proposed Public Offering of Comm
Esperion Therapeutics, Inc. Esperion Therapeutics Announces Proposed Public Offering of Common Stock Ann Arbor, Mich., (March 17, 2015) Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Esperion Therapeutics Announces Removal of PPAR Partial Clinical
Esperion Therapeutics, Inc. Esperion Therapeutics Announces Removal of PPAR Partial Clinical Hold for ETC-1002 Conference Call and Webcast on Monday, February 2, 2015 at 4:30 p.m. Eastern Time Ann Arbor, Mich., (February 2, 2015) Esperion Therapeutics, Inc. (NASDAQ: ESPR), an
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734-887-3903 mlowe@esperion.com Esperion Therapeutics Provides ETC-1002 Development Program Upda
Esperion Therapeutics, Inc. Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results Conference Call and Webcast on Monday, November 10, 2014 at 4:30 p.m. Eastern Time Ann Arbor, Mich., (November 10, 2014) Esperion Therap
Read more →ESPREsperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia - ETC-1002-008 study meets primary endpoint - - LDL-cholesterol lowering
Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia - ETC-1002-008 study meets primary endpoint - - LDL-cholesterol lowering significantly greater with ETC-1002 than ezetimibe - - E
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Jordan Kohnstam Westwicke Partners 443.450.4189 jordan.kohnstam@westwicke.com
jordan.kohnstam@westwicke.com Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2014 Financial Results Conference Call and Webcast on Tuesday, August 12, 2014 at 4:30 p.m. Eastern Time Ann Arbor, Mich., (BUSINESS WIRE) Esperion Therape
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Jordan Kohnstam Westwicke Partners 443.450.4189 jordan.kohnstam@westwicke.com Esperion Therapeutics Provides ETC-1002 Development Progr
jordan.kohnstam@westwicke.com Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results Conference Call and Webcast Today, Monday, May 12, 2014 at 4:30 p.m. Eastern Time Ann Arbor, Mich., (BUSINESS WIRE) Esperion Therapeut
Read more →ESPRElliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast Today, We
Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast Today, Wednesday, March 5, 2014, at 4:30 p.m. Eastern Time Plymouth, Mich., (BUSINESS WIRE) Esperion Therapeutics, Inc. (NASDAQ: ESPR)
Read more →ESPRMedia and Investor Contact: Denise Powell BrewLife 510.703.9491 dpowell@brewlife.com Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates Plymo
Media and Investor Contact: dpowell@brewlife.com Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates Plymouth, Mich., November 6, 2013 Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical compan
Read more →ESPRJessica Volchok BrewLife 310.774.3423 jvolchok@brewlife.com Esperion Therapeutics Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholest
jvolchok@brewlife.com Esperion Therapeutics Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholesterolemia Represents Company s First Clinical Study in Robust Phase 2b Program Plymouth, Mich., October 30, 20
Read more →ESPRDenise Powell BrewLife 510.703.9491 dpowell@brewlife.com Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hy
dpowell@brewlife.com Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia Conference Call Today at 8:30 a.m. ET Plymouth, Mich., September 3, 2013 Esperion Thera
Read more →ESPRMedia and Investor Contact: Denise Powell BrewLife 510.703.9491 dpowell@brewlife.com Esperion Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update Plymouth, Mich.
Media and Investor Contact: dpowell@brewlife.com Esperion Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update Plymouth, Mich., August 12, 2013 Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on deve
Read more →ESPREsperion Therapeutics, Inc. [ESPR] to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, July 16, 2013 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. [ESPR], a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercho
Read more →Competitive Position
How ESPR ranks across every disease it competes inCompetitive Position is a premium feature
See how ESPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial